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In addition to the well-characterized sodium-dependent excitatory amino acid 
transporters (EAATs) present in the mammalian CNS, a chloride-dependent, sodium- 
independent transporter has also been identified that is capable of mediating the uptake of 
L-glutamate. Named system x ,, this transporter is an obligate exchanger that normally 
couples the export of intracellular L-glutamate with the import of extracellular L-cystine. 
Using the human tumor cell line SNB-19 that expresses high levels of system x.., we used 
a fluorescent-based assay that allowed system x̂  -mediated exchange of L-glutamate and 
L-cystine to be followed in real time to assess substrate activity. Interestingly, those 
compounds that proved to be the most potent competitive inhibitors (e.g. L-quisqualate 
and 4-S-CPG) also proved to be the least active as substrates, suggesting that distinct 
structural features may control binding and translocation. In the second portion of work 
we studied the neiirotoxic compoimd P-N-oxalyl-L-a,P-diaminopropionic acid (P-L- 
ODAP) and its action at system x^. P-L-ODAP is found in the seeds of LatAyrw.; 
(chickling peas) and is thought to be an active agent in human lathyrism. We 
investigated the action of P-L-ODAP and a series of isomers and homologues at the 
chloride-dependent L-glutamate transporter through [^H]-L-glutamate uptake assays. P- 
L-ODAP produced levels of inhibition similar to what is found in the presence of 
endogenous substrate L-cystine while the two isomers, P-D-ODAP and a-L-ODAP, 
along with the homologues y-L-ODAB and y-D-ODAB proved to be relatively inactive.
A more extensive kinetic analysis revealed P-L-ODAP to be a competitive inhibitor of 
chloride-dependent L-glutamate uptake and a substrate at system x, with activity 
comparable to L-cystine. Lastly, we investigated the relationship between levels of 
system x̂  activity and the maintenance of intracellular glutathione concentrations in 
several glioma-deiived cell lines. By comparing the effect of system x̂  inhibitors, such 
as 4-S-carboxyphenylglycine, with other inhibitors of glutathione biosynthesis, such as 
buthionine sulfoximine, on glutathione levels, the contribution of the transporter in 
supplying extracellular precursors for this antioxidant can be estimated. We observed 
that inhibition of system x̂  led to a time-dependent decrease in intracellular glutathione 
levels. However, we also found that the levels of x̂  activity varied among the cell lines, 
even though the rates of glutathione utilization appeared similar. These results suggest 
that the amount of cystine transported through system x, for glutathione maintenance 
may vary between the glioma cell lines.
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Chapter 1: Background and Introduction
Glutamate is a biologically important amino acid which can be oxidized to form 
a-ketoglutarate and participate in the Krebs cycle or used as a component in the 
biosynthesis of proteins. With a pK̂ Rp̂ ,,) = 4.07, a pK(,._cooH) = 2.10, and pK(g_NH3+) = 
9.47, glutamate is an acidic amino acid that carriers an overall negative charge at pH = 
7.4 (Zubay, 1996). The L-glutamate enantiomer is the predominant form found in 
biological systems and is the main excitatory amino acid in the mammalian CNS that 
participates in fast synaptic communication, as well as more complex signal processes 
needed in learning and memory (Cotman et al., 1995).
Excitoto/y wMfMO ocW receptor.;
Upon release into the synapse, L-glutamate sends its message by activating 
various ionotropic and metabotropic receptors. Three classes of ionotropic receptors 
have been identified and named after the selective agonists used in their discovery: N- 
methyl-D-aspartate (NMD A), kainate (KA), and a-amino-3-hydroxy-5-methyl-4- 
isoxazole propionate (AMPA) (Cotman etal., 1995). Kainate and AMPA receptors gate 
primarily a Na"" current following ligand stimulation, while N-methyl-D-aspartate 
(NMDA) receptors are permeable to both Na  ̂and Ca^ ions. The movement of Ca^ ions 
through the NMDA receptor is an important component in more complex signaling 
processes, such as long term potentiation and developmental plasticity (Cotman et al., 
1995). The metabotropic receptors are G protein-coupled and contain eight known
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
subtypes that have been divided into three separate groups based on pharmaqological 
specificity (Pin and Duvoisin, 1995). The subtypes mGluRl and mGluR5 are Group I 
receptors coupled to the Gq protein. When activated, Gq subunits subsequently increase 
phospholipase C activity and increase inositol triphosphate levels (Masu, 1991). Group II 
includes mGluR2 and mGluR3 receptors and Group III contains mGluR4, mGluR6, 
mGluR7, and mGluRS sub̂ p̂es. These latter two groups are directly coupled to the G; 
protein complex. When activated, a G; subunit inhibits adenylate cyclase activity that 
subsequently reduces the conversion of ATP into adenosine 5-monophosphate (cAMP) 
(Genazzani et al., 1993).
Three processes may contribute to the termination of post-synaptic L-glutamate 
excitatory signals: diffusion, enzymatic degradation, and transportation out of the 
synaptic cleft. Enzymes for L-glutamate degradation are not present in the synapse and 
studies by Clements (1992) indicated that changes in synaptic levels of l-glutamate 
cannot be solely attributable to diffusion. Thus movement of L-glutamate out of the 
synapse by transport proteins is felt to be a m^or contributor to the termination of EAA 
signals, replenishment of astrocytic L-glutamate pools, and the prevention of the 
overstimulation of ionotropic L-glutamate receptors (Takahashi et al., 1997), Five high- 
afflnity sodhim-dependent L-glutamate transporters have been characterized in humans 
and are members of system x*o. These proteins are placed into the solute carrier 1 
(SLCl) gene category which includes two isoforms of system ASC, the Na -̂dependent
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
neutral amino acid transport system. Glutamate aspartate transporter 1 (GLASTl), 
predominantly found on glial cells, was first isolated from rat brain and found to have a 
weight of 66-KDa (Storck, 1992). Following immunoscreening with an antibody 
generated against a 64-KDa protein, glutamate transporter 1 (G LTl) was originally 
identified from a rat brain cDNA library (Pines, 1992). The isolation of 3,442-base-pair 
cDNA from rabbit small intestine led to the characterization of the excitatory amino acid 
carrier 1 (EAACl) (Kanai et al., 1992). Homologues for GLAST, G LTl, and EAACl 
were later cloned from the human cortex and named excitatory amino acid transporters 1, 
2, and 3 respectively (EAATl, EAAT2, and EAAT3) (Arriza et al., 1994). Two other 
high affinity Na^-dependent L-glutamate transporters were later cloned from a human 
cDNA library. EAAT4 is the predominant form in cerebellar slices and EAATS is 
present in the mammalian retina (Fairman et al., 1995; Arriza, et al., 1997).
The high-affinity, sodium-dependent l-glutamate transporters are dependent upon 
an extracellular electrochemical Na  ̂gradient established by membrane bound (Na^+K^)- 
ATPases. These transporters utilize free energy stored in the charge and concentration 
separation of Na  ̂and K* ions and cotransport one glutamate molecule, 3 Na  ̂ions, and 
one proton into the cell with subsequent efflux of one ion out of the cell (Kanner et al., 
1982; Wadiche et al., 1995). During ischemic events when Na* gradients are abolished, 
1—glutamate transport is seriously compromised. Extracellular L-glutamate levels may 
actually rise due to efflux of 1—glutamate through Na -̂dependent transporters (Koch et 
al., 1999; Rossi et al., 2(XX)). Excessive levels of L-glutamate in the synaptic cleft can 
overstimulate ionotropic EAA receptors and lead to subsequent neuronal death; a 
phenomenon termed excitotoxicity (Choi, 1994). Acute forms of excitotoxicity are
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
believed to occur following head trauma, stroke, and seizure activity. Pathological 
findings in chronic neurological disorders also show selective neuronal loss through 
excitotoxic damage (Choi, 1988; Leigh et al., 1996). Some chronic CNS diseases 
include: Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis 
(ALS).
ChkrWe-e/gpgWent g/wtomarg fra/wport
The high afflnity uptake of L-glutamate can also occur by a second system which 
is Na -̂independent and Cl -dependent. Initial characterization of this transport system 
was performed in a rat astrocytoma cell line (Waniewski and Martin, 1984). In the 
LRM55 cells, 35% of high-affinity L-glutamate uptake was mediated by this transporter. 
Earlier work following the binding of [^H]-L-glutamate in synaptic plasma membranes 
revealed an L-glutamate binding site which was potently inhibited by 2-amino-4- 
phosphonobutyric acid (AP4), L-a-aminoadipate, and quisqualate and relied heavily 
upon Cl and Ca^ (Fagg etal., 1982). Later, L-glutamate binding studies in rat astrocyte 
membranes helped elucidate a site which was Cl -dependent, Ca^ insensitive, and 
inhibited by L-a-aminoadipate and quisqualate but not AP4 (Bridges et al., 1987). 
Autoradiography studies in rat brain slices delineated a Cl -dependent L-glutamate 
binding site which was also inhibited by L-a-aminoadipate and quisqualate but relatively 
insensitive to AP4 (Anderson et al., 1990). The differences in ionic sensitivity and 
pharmacological profiles between the three independent studies may represent binding 
site subtypes or differences in methods used. However, studies in hippocampal slices and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
synapüc plasma membranes highlight similarities between the high-afflnity chloride 
dependent L-glntamate transport system and the earlier characterized Cl -dependent, 
osmotically sensitive L-glutamate binding site. Osmotic sensitivity, the ability of low 
temperatures to abolish Cl -dependent L-glutamate binding, and the visual presence of 
vesicles in synaptic membranes all suggested that the Cl -dependent L-glutamate binding 
site and the high affinity Cl -dependent L-glutamate transporter were mediated by the 
same or closely related protein (Pin et al., 1984; Bridges et al., 1986). The link between 
f  H]-L-glutamate binding and L-cystine was established when L-cystine was shown both 
to inhibit 80% of Cl -dependent L-glutamate binding in synaptic membranes and to 
stimulate glutamate efflux in transport experiments (Kessler etal., 1987).
The coupled transport of cystine and glutamate by a Na^-independent transporter 
termed system x,. was first described in human diploid fibroblasts. The conclusion that 
glutamate and cystine were intracellularly accumulated by the same transporter was 
supported by a number of observations. First L-cystine and L-glutamate mutually 
inhibited the transport of each other in initial velocity uptake experiments under chloride- 
dependent conditions. Second the K„ for L-cystine uptake was similar to the inhibitory 
K; value of L-cystine on L-glutamate uptake and vice Finally, pharmacological
assays of various amino acids produced similar levels of inhibition or lack thereof on 
both L-cystine and L-glutamate uptake (Bannai and Kitamura, 1980). A subsequent 
study estimated L-cystine and L-glutamate to possess an overall negative one charge at
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physiological pH when transported by the Na^-independent transport system. Potent 
inhibitors of system included DL-a-aminoadipate, DL-a-aminopimelate, and DL- 
homocysteate (Bannai and Kitamura, 1981). Later studies in human diploid fibroblasts 
showed that in an environment which depleted intracellular L-glutamate levels, Cl - 
dependent L-cystine upake and Cl -dependent L-glutamate transport were both seriously 
compromised (Bannai, 1986). Additional experiments in the the same study revealed an 
L-cystine induced efflux of L-glutamate of 1.9 nmol/min mg protein and an L-cystine 
upake rate of 1.66 nmol/min mg protein. From these studies it was concluded that the Cl 
-dependent glutamate/cystine transporter, system Xg, was an anionic exchanger which, 
under normal physiological conditions, used a high intracellular L-glutamate 
concentration to drive the import of cystine with a concurrent efflux of glutamate. From 
the above efflux and transport rates, it appears that cystine influx and glutamate exodus 
occiu" at a 1:1 ratio. Under experimental conditions, this transporter is also able to 
homoexchange intracellular and extracellular glutamate (Bannai, 1986).
Recent cloning of system x̂  has helped elucidate its molecular architecture and 
enabled the system to be studied in Xenopwj oocytes (Sato et al., 1999). cRNA prepared 
from mouse macrophage cDNA was injected into oocytes. From Cl -dependent L-cystine 
uptake studies, it was ascertained that two clones, Cm30 and Dr4, were needed for proper 
transport. Cm30 encodes the cell surface glycoprotein 4F2hc. The slightly hydrophobic 
4F2hc protein has one transmembrane domain and belongs to the 4F2 group of 
transporters which includes system Land y^L. Dr4 encodes the 502 amino acid protein 
xCT. This protein has a relative molecular mass of 555 kDa, twelve predicted 
transmembrane domains, and is much more hydrophobic than 4F2hc. It is speculated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
that xCT functions as an antiport transporter. 4F2hc and xCT are joined by a critical 
sulhydryl linkage to form a heteromuldmeric polypeptide. This polypeptide, when 
expressed on the cell surface, forms system x̂  (Figure 12). However, recent studies 
have also shown the transient expression of system x̂  in oocytes transfected with xCT 
and rBAT cDNA (Wang et al., 2003).
Recent cloning in a human undifferentiated teratocarcinoma cell line, NT2, 
yielded a sequence termed SLC7A11 which encodes the putative 501-amino acid protein, 
hxCT, that shares 89% identity with mouse xCT (Bassi et al., 2(X)1). Cloning in human 
fibroblasts has been reported to yield two cDNA clones for xCT. Clone 1 cDNA 
contained 1861 ribonucleotides while clone 2 cDNA contained 5626. The last 925 
ribonucleotides of clone 1 are identical to the first 925 ribonucleotides of clone 2. 
Approximately ninety percent of seqiience homology is shared between the putative 501 
amino acid protein translated from clone 1 and mouse xCT (Sato, 2000). In the human 
retinal pigment epithelial cell line, ARPE-19, a 2482 bp-long cDNA segment was 
isolated. The encoded xCT protein from the ARPE-19 clone shares 89% sequence 
identity with mouse xCT (Bridges et al., 2001). In the human glioma cell line U87 
treated with DEM, a 2000 bp cDNA clone for xCT was found. When compared to mouse 
xCT, the encoded protein, hxCTb, shared 86% amino acid sequence identity (Kim et al., 
2001).
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Trwwporf o/rofe G5H b(OjyMfAg.rû
The physiological importance ôf system x, was explored by studying the 
metabolic conversions of glutamate and cystine following transport into human diploid 
fibroblasts (Bannai and Kitamura, 1980). Fbllowing a two minute uptake study, the 
majority of [^Hj-L-cysdne was recovered as L-cysteine and glutathione whereas 95% of 
L-glutamate remained unchanged. These biochemical observations along with the 
finding that intracellular glutathione levels fall precipitously in L-cystine depleted media 
indicate that L-cysdne transport through system x̂  may be a rate limiting step in the 
biosynthesis of glutathione (Banai et al., 1977). Cystine and its reduced counterpart L- 
cysteine are brought into the cell through other transporters. Transport of cysteine 
through the sodium-dependent transport system ASC and the sodium-independent system 
L has been observed (Bannai, 1984 and Shanker, 2(X)1). Cysteine transport into cultured 
primary astrocytes and neurons by system x*,- has also been reported (Shanker, 2001). 
EAATS when expressed in Xenopi» oocytes transported L-cysteine with a K^ of 190 piM 
(Zerangue et al., 1996). In rat alveolar type II cells, cystine transport was largely by 
system x̂ o (Knickelbein et al., 1997). In human endothelial and pancreatic cells, L- 
cystine was found to be transported by y-glutamyl transpeptidase (Cotgreave et al., 1994; 
Sweiry et al, 1995).
G/wWAfOMg cyc/g
Glutathione is the m^or mammalian cell thiol that serves in the storage and
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transport of cysteine and is a key intermediate in a wide range of biochemical processes. 
Acting as a nucleophile, it can reduce ribonucleotides into deoxyribonucleotides and help 
in maintaining other antioxidants such as ascorbate and a-tocopherol in their reduced 
states. GSH can act directly or enzymatically with GSH peroxidases and GSH S- 
transferases in the neutralization of reactive oxygen species, free radicals, and 
electrophiles. GSH directly coiyugates with various drugs and endogenous molecules 
and assists in their metabolism (Meister, 1985).
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine and is 
synthesized by two energy-dependent enzymatically coupled reactions (Rgure 1.1). L- 
Glutamate and L-cysteine are first joined through the action of y-glutamylcysteine 
synthetase. This step is inhibited by both GSH and L-buthionine-[S,R]-sulfoximine 
(Griffith and Meister, 1979). The second step, catalyzed by GSH synthetase, adds L- 
glycine to y-glutamylcysteine to form GSH. The breakdown of GSH or GSSG occurs in 
the presence of y-glutamyl transpeptidase. This enzyme is located predominately on the 
extracellular side of the plasma membrane. The degradation occurs enzymatically by y- 
glutamyl transpeptidase bringing an acceptor into proximity with the y-glutamyl group. 
Some acceptors include amino acids and water. The y-glutamyl-amino acid is transported 
into the cell and cleaved by y-glutamyl cyclotransferase. The amino acid is freed and the 
y-glutamyl moiety is converted to the ring structure 5-oxoproline (Meister, 1989). Due to 
the stability of the amide bond in 5-oxoproline, the conversion of this five member ring 
into L-glutamate requires ATP and the enzyme 5-oxoprolinase. L-2-Oxothiazolidine-4- 
carboxylate, an exogenous substrate for 5-oxoprolinase, is converted to L-cysteine in the 
presence of enzyme. The last step of the y-glutamyl cycle includes the cleavage of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cysteinylglycine into individual cysteine and glycine molecules by dipeptiduse (Meister, 
1991; Meister et al., 1983).
Trwwport q/cyjrine by jyffg/n x / o rote Zimiring Jtep m b(Ojynrbg.rir
Lowered extracellular L-cystine levels and inhibition of L-cystine uptake by L- 
glutamate separately decreased intracellular GSH levels in the neuronal hybridoma cell 
line N 18-RE-105. This led to cell lysis and suggested the importance of L-cystine uptake 
through system Xc for maintenance of intracellular GSH levels (Murphy et al., 1989). 
Later studies in immature cortical neurons showed L-cystine transport to be blocked with 
subsequent cell death by system Xg inhibitors quisqualate, homocysteate, ibotenate, and 
L-glutamate (Murphy et al., 1990). In the rat glioma cell line C6, a lOh incubation with 
excess glutamate or media with a low cystine concentration precipitously decreased 
intracellular GSH levels (Cho and Bannai, 1990). Increasing the L-cystine amotmt in the 
presence of a high L-glutamate concentration restored GSH levels. These results provide 
another example of the role of system x, in GSH maintenance. However, following 
separation of a rat neuronal-glial coculture, glial intracellular GSH levels were 
maintained by L-cystine, whereas neuronal GSH levels were sustained by uptake of L- 
cysteine released from the glial cells (Sagara et al., 1993). Consistent with Sagara's 
flndings, it was found that intracellular GSH levels in rat primary neuronal cells were 
maintained by transport of extracellular L-cysteine (Kranich et al., 1996).
Early work in our lab has led to an extensive pharmacological proflle of Cl - 
dependent L-glutamate uptake in LRM55 cells (Patel et al., 2004). From the initial
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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inhibition studies, determinations were made on several of the most potent inhibitors.
It was further ascertained that these compounds were competitive inhibitors. The third 
chapter in my work deal̂  with further elucidation of the action of these compounds at 
system Xg. By modifying a fluorometric assay first developed by Nicholls to measure I— 
glutamate efflux from synaptosomes, ionic dependency of L-cystine induced L-glutamate 
efflux was explored. Following this, the competitive inhibitors were analyzed for their 
ability to stimulate L-glutamate efflux as should occur in heteroexchange. Comparisons 
between the rate of L-glutamate efflux in the presence of the endogenous system Xg 
substrate L-cystine with those rates induced by the competitive inhibitors allowed these 
compounds to be classified as either substrates, partial substrates, or non-transportable 
inhibitors. The second portion of work focuses on establishing the activity of p-L-ODAP 
at system Xg. This glutamate analogue is generally accepted as the causative agent in 
motor neuron degeneration following consumption of seeds from plants belonging to the 
genus. Cl-Dependent [^H]-L-glutamate uptake and the recently modified 
fluorometric assay were used as tools to determine the kinetic properties and substrate 
properties of P-L-ODAP. P-L-ODAP was found to be a competitive inhibitor at system 
Xg with a Kj around 100 pM. This non-protein amino acid also produced an L-glutamate 
efflux rate that was comparable to that mediated by L-cystine. These findings may 
further elucidate the biochemical role P-L-ODAP plays in neurological pathologies 
associated with lathyrism. The last portion of my work focuses on the relationship 
between Cl -dependent L-glutamate uptake activity and maintenance of GSH levels in 
human glioma cells. A series of four human glioma cell lines were screened for system 
Xg activity. Intracellular GSH levels were also measured and compared to the values
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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generated in the kinetic studies. It was hypothesized that the intracellular GSH levels in 
the cell lines expressing the highest activity of Cl -dependent L-glutamate uptake would 
be the most dependent on L-cystine uptake through system x ,. Our findings show that 
although the cell line expressing nearly triple the activity of Cl -dependent L-glutamate 
uptake had the highest control GSH level, maintenance of this antioxidant was least 
dependent on L-cystine uptake through system x,' in the SNB-19 ceU line. These cells 
appear to possess an alternative mechanism to provide the rate-limiting GSH precursor.
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Figure 1.1. y-Glutamyl Cycle.
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Rgure 12. Schematic representation of the heteromeric amino acid transporters.
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Specific Aims:
I) Develop a fluorometrically-coupled assay to measure real-time I—glutamate efflux 
rates and differentiate substrates from non-substrates of system Xg.
a) Elucidate ionic dependence of L-cystine induced L-glutamate efflux.
b) Measure L-glutamate efflux rates in the presence of system Xg inhibitors.
x / wzff mdwcg L-gWomatg g^nx rotgj tbat we WtenwWeiJ in the
prejence q / non-iranjportabie inbibitor.;.
Compétitive inbibtiorĵ  q/jy^tem Xg wtib fimtiw cbemicoZ jti"wcfwe.r witi bebove 
tiijg^rentiy W tbe cy.$tine/gb<rwMWe obtigWo/y excbwiger.
n) Elucidate the interaction of ±e 1—glutamate analogue P-L-ODAP with system Xg .
a) Assay the action of P-L-ODAP at system Xg by measuring its effect on chloride- 
dependent L-glutamate uptake.
b) Perform a kinetic analysis to elucidate P-L-ODAP's mode of inhibition.
c) Using the fluorescence assay, determine whether P-L-ODAP is a system Xg 
substrate, partial substrate, or non-transportable inhibitor.
/S-L-ODAP is a JKbsti-gte W jyjfem Xg wbicb may provitile a roftie q/̂ entiy to occwmw/We 
fbü newotoxin fnti-ocetiwiwiy anti cfew ti^om tbe .^nqptic cie/r.
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III) Evaluate the relationship between system activity and maintenance of GSH levels 
in human glioma cells.
a) Determine system activity by measuring values in a series of four human 
glioma cells.
b) Determine GSH turnover in the four cell lines by measuring intracellular GSH 
levels following incubation with buthionine sulfoximine.
c) Determine time course changes in intracellular GSH levels following incubation 
with the competitive system x, inhibitor 4-S-CPG.
d) Identify potential alternate routes of entry for GSH precursors.
Glioma cell lines with the highest total intracellular GSH levels w ill express the highest 
Cf-efgpg/Kfgnt iL-g/wfo/nafg wptoAg octzvify.
znfracgZZw/w G S ff Zeveü in gZzoma ceZk the C f-
(ZgpgwZgnr wpZate actzvzfy wzZZ zAg mojt (ZqpgwZenf on Z,-cyj/fng
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Chapter!: Methods and Materials
CeZZ CwZZwrg
Human glioma cell lines (obtained from American Type Culture Collection 
Manassas, VA) were grown in DMEM/F12 medium (pH 7.4) containing ImM pyruvate, 
14.28 mM NaHCOg, 25 mM HEPES and supplemented with 10% fetal bovine serum and 
a mixture of penicillin (100 U/ml), streptomycin (100 U/ml), and amphotericin B (0.25 
pg/ml). Final concentrations (mM) of amino acids are as follows: L-alanine (0.05), 
arginine (0.85), L-asparagine - H^O (0.05), L-aspartic acid (0.05), L-cysteine - H^O 
(0.13), L-cystine - 2HCL (0.10), L-glutamate (0.05), L-glutamine (23), glycine (0.25), L- 
histidine HCl - H2O (0.15), L-isoleucine (0.42), L-leucine (0.45), L-lysine HCl (030), L- 
methione (0.12), L-phenylalanine (0.22), L-proline (0.15), L-serine (025), L-threonine 
(0.45), L-trypotophan (0.04), L-tyrosine 2Na 2 H^O (0.31), L-valine (0.45). Cell lines 
were cultured in 150 cm̂  flasks (Coming) and maintained at 37 °C in a humidiOed 
atmosphere of 5% CO;. Cells were lifted from the flasks by the addition of 10 ml trypsin 
(0.05% final concentration) for 3-5 minutes for passage every three to five days. At this 
time cell culture stocks for cryopreservation were prepared by maintaining 1x10̂  to 2x10  ̂
cells in DMEM/F12 supplemented with 10% DMSO and storing at -196 °C under liquid 
N;. In the fluorometric assays, SNB-19 glioma cells were grown in Ham's F-10 medium 
(pH 7.4) containing 1 mM pyruvate and 16 mM NaHCO  ̂and supplemented with 15% 
fetal calf semm. For individual experiments, cells were seeded in 12-well culture plates
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at a density of around 5xl(X*to 2x10  ̂cells/well and maintained for 3 to 4 days until just 
confluent. Two wells per plate were designated as protein wells.
CeZZ Transport A$.;qy
The uptake of glutamate into cultured cells was quantified using a modification of 
the procedure described by (Martin, 1979). Individual wells, after removal of culture 
media, were rinsed three times and pre-incubated in 1ml HEPES buffered (pH 7.4) 
Hank's balanced salt solution (HBHS) at 30 °C for 5 min. Where indicated the HBHS 
was altered by ionic substitution to isolate the Na* and Cl -dependent transport systems. 
The buffers contained: (1) total (Na  ̂and Cl -dependent): 137 mM NaCl, 5.1 mM KCl, 
0.77 mM KH2PO4 , 0 . 7 1  mM MgS0 4 .7 H2 0 ,T .l mM CaCl;, 10 mM D-glucose, 10 mM 
HEPES; (2) Na'̂ -dependent: 130 mM Na gluconate, 5 mM K gluconate, 1.1 mM Ca 
gluconate, 0.77 mM KH2PO4 , 0.71 mM MgSO^ 7 H2O, 10 mM D-glucose, 10 mM 
HEPES and (3) Cl -dependent: 137.5 mM choline Cl, 5.36 mM KCl, 0.77 mM KH2PO4 , 
0.71 mM MgSO  ̂ 7 H2O, 1.1 mM CaCl;, 10 mM D-glucose, 10 mM HEPES. Uptake 
was initiated by aspiration of the preincubation buffer and the addition of a 500 pi aliquot 
of the appropriate transport buffer containing [^H]-L-glutamate (10-500 pM, Enal 
concentration). In those assays that evaluated inhibitor activity, the 500 pi aliquot of 
transport buffer contained both the [^H]-L-glutamate and potential inhibitor to ensure 
simultaneous addition. Following a 5 min incubation at 30 °C, the assays were 
terminated by three sequential 1 ml washes with ice cold buffer and then the cells were 
dissolved in 1 ml of 0.4 M NaOH for 24 hours. An aliquot (200 pi) was then transferred
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into a 5 ml glass scintillation vial and neutralized with the addition of 5 pi glacial acetic 
acid followed by 3.5 ml Liquiscint® scintillation fluid (National Diagnostics) to each 
sample. Incorporation of radioactivity was quantified by liquid scintillation counting 
(LSC, Beckman LS 6500). Values reported are corrected for non-specific uptake (e.g., 
leakage and binding) by subtracting the amount of |^H]-L-glutamate accumulation at 4 
°C. Protein content was determined by the bicinchoninic acid (BCA) method (Pierce) 
(Smith et al., 1985). ïünetic constants of substrates and inhibitors were determined using 
this same procedure by varying the concentrations of L-glutamate and inhibitors with 
respect to and K, values (for review see (Christensen, 1975).
GSH /{gcyc/mg
The GSH recycling assay introduced here was first reported by Tietze, (1969) 
with modifications by Griffith, (1980) and Anderson, (1985). GSH in the presence of 
5 3  '-dithiobis(2-nitrobenzoic acid) (DTNB) is oxidized to GSSG with a concurrent 
formation of 5-thio-2-nitrobenzoic acid (TNB). GSSG is recycled back to GSH in the 
presence of GSH reduct^e and the cofactor NADPH. The stoichiometric formation of 
TNB was monitored at Â ^̂  and is proportional to the total amount of GSH.
A standard curve was run during GSH detection of unknowns. Seven sequential 
GSH amounts ranging from 0.039 nmols to 1.25 nmols were added to separate wells 
containing 50 pi of DTNB from a 2.4 mM stock, 50 pi of NADPH taken from a 0.8 mM 
stock, and 50 pi of GSH reductase taken from a 2.65 U/mL stock. The total volume in 
each microplate well was 200 pi and the reaction was initiated by the addition of
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NADPH. DTNB, GSH reductase, and NADPH stock solutions were all made in a stock 
buffer at pH 73  containing sodium phosphate (143 mM) and Na^-EDTA (6.3 mM). The 
microplate was shaken and placed in a Molecular Devices Thermomax microplate reader 
with absorbance read at 405 nm by SOFTmaxPRO software (version 12.0) at 10 second 
intervals for 5 minutes. Slopes from the series of eight standards were taken and plotted 
as a function of GSH amount to generate a standard curve. Slopes from the unknowns 
were interpolated Aom a linear fit of thé standard curve to generate calculated amounts. 
A background rate was determined in the presence of 50 pi 1%SSA, 50 pi NADPH, 50 pi 
DTNB, and 50 pi GSH reductase.
Prior to the harvesting of cells for total GSH detection, 1 mL of 0.4 NaOH was 
added to designated protein wells. The cells were dissolved for 24 h and total protein 
content was determined via the BCA method. Test wells were rinsed Ix  with HBSS. 1% 
SSA solution (1 mL) was then added to each well and the cells were lifted by the 
scraping action of a flame-bent pasteur pipette. The homogenate was vortexed and 
microfuged on high for approximately 1-3 minutes. After one series of freeze/thaw 
cycles, 50 pi of supernatant was used for total GSH detection.
f/Mororngtzc
Fluorometric determination of L-glutamate efflux was quantified using a 
modification of the procedures described by Nicholls and Shira, (1986) and Vesce et al., 
(1997). NADPH fluoresence was quantified using a Hitachi F-2000 fluorescence 
spectrophotometer fitted with a thermostatted cuvette holder and a 1 cm̂  electronically
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
21
driven magnetic stirrer platform. Confluent monolayers of SNB-19 glioma cells grown on 
coverslips were paired, placed back to back and rinsed in the appropriate HBHS buffer 
for 10 min. The coverslips were transferred and incubated in a stirred quartz cuvette 
containing 2 ml HBHS at 30 °C. Assays were initiated with the addition of NADP' (1 
mM) at 0 sec followed by GDH (33 U) at 60 sec. Subsequent additions of l^cystine or 
other potential substrates (50-500 piM) were made as detailed in the figure legends. Each 
experiment was terminated with the addition of Triton X-100 (0.5%) to determine the 
total amount of L-glutamate in the cells. The amount of L-glutamate efflux was 
determined via a standard curve generated in an identical experiment but omitting the 
cells. Following the enzyme, seven sequential additions of 4 nmol L-glutamate were 
made yielding a non-linear curve. Rates of L-glutamate efflux are reported as mean ± 
S.E.M and are corrected for non-specific efflux (e.g. leakage) by subtracting the amount 
of L-glutamate efflux in the absence of L-cystine.
U-373, SW-1088, SNB-19 and CCF-STTGl glioma cell lines were purchased 
from American Type Culture Collection (ATCC) (Manassas, VA). General cell culture 
supplies were purchased from Becton Dickinson (Franklin Lakes, NJ), Coming (Coming, 
NY), and Life Technologies (Grand Island, NY). L -[3,4-^H]-Glutamic acid was 
purchased from Dupont NEN (Boston, MA). L-Glutamate, L-cystine, L-a-aminoadipate, 
D-aspartate, dihydrokmnate, kainate, L-homocysteate, L-homocysteine sulphinate and L- 
serine-O-sulphate were purchased from Sigma (St. Louis, MO). 2-Amino-2-norbomane- 
carboxylic acid was purchased from Aldrich (Milwaukee, W I). (RS)-4-
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bromohomoibotenate, quisqualate, ibotenate, 4-S-carboxyphenylglycine, p-L-ODAP, 
AP4, NMDA and AMPA were purchased from Tocris (Ballwin, MO). (1S,3S)-13- 
homo-ACPD was obtained from Kenneth Curry. L-Ny-P-chlorophenyl-glutamine from
Christopher Sean Esslinger. 2,4-MPDC, L-rrww-2,4-PDC, L-rrwM-23 -PDC and L-onfz- 
gwZo-3,4-MPDC were synthesised as described (Bridges et al., 1991; Bridges et al., 1993; 
Bridges et al., 1994; Humphrey et al., 1994; Esslinger et al., 1998). AH other chemicals 
were purchased Aom Sigma (St. Louis, MO) and VWR (West Chester, PA).
SratzjfzcoZ A/zaZy.yw
Student t-Tests were performed on the data. For analyses, two group t-Tests with 
unpaired data were used. An F probability of < 0.05 indicated statistically different 
variances so a t-Test with unequal variance was performed. An F probability of > 0.05 
indicated equal variances so a t-Test with equal variance was performed. Where 
indicated, p < 0.05 or p < 0.01 were considered significant.
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Chapter 3: Differentiation of Substrate and Non-Substrate Inhibitors of Transport 
System x, : an Obligate Exchanger of L-Glutamate and L-Cystine.
Introduction
High-affinity glutamate transporters are credited with numerous functions within 
the mammalian central nervous systems (CNS), including roles in: signal termination, 
transmitter recycling, excitotoxic protection, and the regulation of extracellular glutamate 
levels. Many of these activities have been ascribed to the excitatory amino acid 
transporter (EAAT) subtypes 1-5, which are members of the x^  ̂ family of electrogenic, 
Na^-dependent anionic amino acid transporters (for review see: Bridges et al., 1999; 
Danbolt, 2001; Palacin et al., 1998). Another transport system, referred to as system x^, 
has been identified which is also capable of translocating L-glutamate, yet is readily 
distinguished from system x*o', in that it is Na^-independent, Cl -dependent, 
electroneutral, and acts as an obligate exchanger of L-glutamate and L-cystine. Recently 
cloned from mouse and human cDNA libraries (Bassi et al., 2001; Sato et al., 1999), 
system x̂  is a member of the newly characterized glycoprotein-associated amino acid 
transporter (gpaAT) family (Verrey et al., 2000). The transporters in this family are all 
obligate exchangers that must form heterodimers with a glycoprotein subunit (often 
referred to as the heavy chain) for functional surface expression. In the instance of 
system x ,, the heterodimer is formed between the transporter subunit xCT, a 502 amino 
acid containing protein with twelve putative transmembrane domains, and 4F2hc, a cell 
surface glycoprotein (initially referred to as CD98 in mouse) that is also associated with 
transport systems L and y^L (Sato et al., 1999).
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Rather than function to concentrate L-glutamate intracellularly, this system is 
thought to utilize normally high intracellular levels of L-glutamate to drive the import of 
L-cystine. Given this directionality, interest has focused on both the movement of 
cystine into cells as a precursor for glutathione biosynthesis (McBean, 2002; Sagara et 
al., 1993a), as well as the efflux of glutamate out of cells as a potential route leading to 
excitotoxic neuronal injury (Barger et al., 2001; Espey et al., 1998; Murphy et al., 1989; 
Piani et al., 1994). As expected, system x̂  activity can be quantised using either L- 
glutamate or L-cystine as a substrate, and in both instances, uptake is Cl -dependent and 
Na^-independent. Glutamate uptake through this system is competitively inhibited by 
cystine and vice verfo (Bannai et al, 1980; Cho et al., 1990). System x, -mediated 
transport has been reported to occur in primary cultures of neurons (Sagara et al., 1993b) 
and astrocytes (Allen et al., 2001; Gochenauer et al., 2001), C6 glioma cells (Cho et al., 
1990), human gliomas (Ye et al., 1999), retinal Muller cells (Kato et al., 1993), microglia 
(Piani et al., 1994), as well as outside the nervous system in fibroblasts, hepatocytes, 
alveolar type II  cells, macrophages, renal tubule cells, and umbilical vein endothelial 
cells (for review of cellular distributions see Ishii et al., 1992).
The amounts of system x,. activity typically found in many standard 
neurochemical preparations are relatively low, especially when compared to the levels of 
EAAT activity. Indeed, the first indications that system x,. was present in brain can be 
traced back to studies quantifying the distribution and pharmacology of Cl -dependent L- 
[^Hj-glutamate binding, rather than studies directly measuring uptake (Anderson et al., 
1990; Bridges et al., 1987a; Bridges et al., 1987b). Advantageously, the identification of 
CNS-derived tumor cell lines expressing increased levels of Cl -dependent L-[^H]-
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glutamate uptake allowed the transport system to be more selectively characterized 
(Murphy et al., 1989; Waniewski et al., 1984). The resulting pharmacological profiles 
from these cell lines are consistent with the activity of system as characterized in non- 
neural tissue, such as fibroblasts (Bannai et al., 1980) and hepatocytes (Takada et al., 
1984). Early work in the Bridges lab has established a pharmacological proEle of potent 
competitive inhibitors of Cl -dependent L-glutamate uptake in the rat spinal astrocytoma 
cell line, LRM55. In the present work, these competitive inhibitors are evaluated for 
substrate specificity with a fluorometric assay that allows the exchange of extracellular L- 
cysdne with intracellular L-glutamate to be directly followed (Nicholls et al., 1987). In 
this manner, competitive blockers can be further classified as either alternative substrates, 
such as ibotenate, or non-substrate inhibitors, such as 4-S-carboxyphenylglycine. The 
results of this study should prove of value in construcdng a more detailed 
pharmacological profile of system x, and identifying analogues with which to investigate 
its physiological roles, as well as provide more insight into the complex physiological 
acdons of a number of widely udlized glutamate analogues, such as ibotenate and 
quisqualate, that appear to interact with this transporter.
Results:
The pharmacological specificity of system x̂  was first delineated by 
systemadcally assaying EAA analogues (500 ;<M) for their ability to block the 
accumuladon of L-[^H]-glutamate (100 /<M) into LRM55 cells under Na^-free condidons 
(equimolar replacement with choline) (Patel etal., 2004). The pharmacological profile
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was distinct from both the EAATs and ionotropic receptors. The most potent inhibitors 
of the Cl -dependent L-glutamate transporter were the acyclic compounds L- 
homocysteate and L-serine-O-sulphate and the cyclic glutamate analogues ibotenate, 
(RS)-4^bromohomoibotenate, quisqualate, and 4-S-carboxyphenylglycine (Table 32). 
Lineweaver-Burk plots and associated kinetic parameters for transport inhibitors were 
estimated by computer analysis using the A.cat kinetic program (BioMetallics Inc.) with 
weighting based on constant relative error. All six compounds were found to be 
competitive inhibitors at system x̂  with IQ values ranging from 5 to 50;zM.
The cellular efflux of L-glutamate can be detected fluorometrically by measuring 
the conversion of NADP^ to NADPH (excitation 370 nm, emission 450 nm) as the 
extracellular L-glutamate is rapidly metabolized by glutamate dehydrogenase (GDH) 
included in the assay mixture (Figure 3.1). In contrast to competition assays, in which 
the accumulation of a single radiolabeled substratejs followed, this approach allows the 
actual exchange of intracellular L-glutamate and extracellular L-cystine by system x̂  to 
be monitored in real time. Thus, cells are grown on coverslips that are suspended in a 
fluorometric cuvette containing assay buffer, GDH, NADI^, and putative 
substrates/inhibitors of system x ,. The amount of L-glutamate in the extracellular 
compartment is quantified using a standard curve generated with defined aliquots of L- 
glutamate (4 nmol) added in the absence of cells (Rgure 32, panel A). The total amount 
of L-glutamate remaining in the cells is determined at the end of each assay following 
lysis with Triton X-100 (Figure 3.3, panel A and B).
To carry out these exchange experiments, SNB-19 cells, a more recently 
identiAed human glioma cell line that exhibits high levels of system x̂  activity was used.
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Advantageously, the increased levels of transporter activity provided a greater signal to 
noise ratio needed for the efflux studies. Initial experiments quantifying the transport of 
L-pH]-glutamate (100 pM) into SNB-19 cells in the presence of Cl and absence of Na'' 
(equimolar substitution with choline) demonstrated an activity of 824 ± 75 pmol/min mg 
protein (n = 3). This represented a little more than 60% of I^[^H]-glutamate uptake 
measured in the presence of NaCl (1340 ± 68 pmol/min mg, n = 3). Measurements made 
under Cl -free conditions (replacement of Cl with equimolar gluconate) yielded uptake 
rates of 577 ± 82 pmol/min mg (n = 3), while the equimolar substitution of sucrose for 
NaCl decreased activity to 55** 11 pmol/min mg protein (n = 6). Kinetic analyses (plots 
not shown) of the Cl -dependent uptake in the SNB-19 cells yielded K^ and values 
(mean ± SEM, n = 4) for L-glutamate of 111 ± 10 pM and 1410 ± 72 pmol/min mg 
protein, respectively.
As depicted in Rgure 3.3, the addition of L-cystine (500 pM) to the fluorometric 
cuvette containing the SNB-19 cells (Panel B) resulted in a marked increase in the 
appearance of extracellular L-glutamate when compared to control (Panel A). Efflux in 
the presence and absence of putative substrates of system x̂  was essentially linear over 
the time couse of the experiment (1500 sec), with the total intracellular pool of L- 
glutamate being about 212 ± 0.72 nmol/mg protein (n = 62). Initial experiments also 
confirmed that basal levels of eÉlux were not increased by the addition of EAA receptor 
agonists NMDA, kainate, and AMPA, or fro/w-ACPD. Similarly, when carried out with 
Na^-free buffer, the addition of L-n-ww-2,4-PDC or D-aspartate, two well characterized 
substrate inhibitors of the Na -̂depepdent EAAT systems, also failed to produce an 
increase in the efflux of L-glutamate.
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The ionic dependence with which substrates of system induced an efflux of L- 
glutamate from the SNB-19 cells was also examined (Table 3.1). When the fluorometric 
efflux assays were carried out in the presence of both Cl and Na'' the rate of efflux 
detected following the addition of L-cystine (initial concentration 250 pM) was 0.61 
nmol/min mg protein. Interestingly, when carried out under Na^-free conditions, the rate 
of efflux increased by more than 50% to 1.03 nmol/min mg protein, suggesting that some 
of the L-glutamate had been recaptured by the cells through the Na^-dependent EAATs 
before it could be metabolized by the GDH. Consistent with the Cl -dependence of 
system x^, replacement of the Cl with gluconate, markedly reduced the rate of efflux 
observed in either the presence or absence of Na''.
The exchange assay was then used to evaluate the potential substrate activity of 
those compounds identified as potent competitive inhibitors. These analogues were 
evaluated at concentrations approximately 10-fold greater than their observed fQ values 
to insure that comparisons were conducted at similar levels of transporter occupancy. 
Because the IQ values had been determined in LRM55 cells, the compounds were also 
tested at these same concentrations as inhibitors of Cl -dependent L-[^H]glutamate (100 
pM) uptake into SNB-19 cells to insure that the relative activities of the compounds did 
not change. As reported in Table 3.2, inclusion of the analogues at the concentrations 
indicated produced very similar levels of inhibition (88 ± 5%, mean ± SD, n = 7) in the 
SNB-19 cells. The resulting rates of efflux produced by the analogues indicated 
considerable variation in their suitability to act as substrates for system x ,. For example 
ibotenate was able to produce an efflux rate that was comparable to that of L-cystine, 
while closely related analogues (RS)-4-bromohomoibotenate and quisqualate showed
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markedly less activity, 55% and 35%, respectively. One of the most potent competitive 
inhibitors identified, was 4-S-carboxyphenylglycine and its ability to act as a non­
substrate inhibitor was further explored by combining it with L-cystine in the efflux assay 
(Figure 3.4). Consistent with its actions as both an effective inhibitor and ineffective 
substrate, 4-S-carboxyphenylglycine did not produce an efflux-mediated increase in 
fluorescence by itself, but was able to attenuate the L-cysüne-mediated efflux when both 
were included in the assay.
Discussion:
The demonstration that EAA receptor agonists commonly used as probes of 
excitotoxic pathology, such as L-quisqualate, ibotenate, and L-homocysteate, also act at 
system \  raises some interesting interpretational issues regarding the mechanisms 
through which these analogues produce CNS damage. On one hand, compounds that act 
as substrates of system x̂ ' could potentially increase extracellular levels of L-glutamate 
and the likelihood of excitotoxic injury by way of an exchange-mediated efflux. That 
this can indeed occur is supported by studies with microglia, where the efflux of L- 
glutamate through system x,. is thought to underlie the excitotoxic phathology observed 
in some CNS infections and diseases (Barger etal., 2001; Espey et al., 1998; Piani et al., 
1994). On the other hand, analogues that act as blockers of system x̂  and limit the 
uptake of L-cystine, could also exacerbate excitotoxic damage as a consequence of 
attenuating glutathione levels and limiting protection from oxidative damage. Such a 
process is consistent with evidence suggesting that oxidative injury and excitotoxicity are
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interacting pathways (Schubert et al., 2001; Trotti et al., 1998; ZLeevalk et al., 1998) and 
the direct demonstration that depleting glutathione levels in primary murine cortical cells 
enhances the extent of NMDA-mediated excitotoxicity (Bridges et al., 1991).
Although the competition assays provide an effective strategy to delineate the 
structural requirements necessary for binding to the substrate domain on the transporter 
protein, they provide little or no insight into those characteristics that are required for 
actual translocation, i.e., the differentiation of substrates from non-substrate inhibitors. 
Traditionally, demonstrating that an analogue acts as a transporter substrate has been 
dependent upon either the compound being available as a radiolabeled derivative or using 
an alternative analytical method to quantily accumulation, such as HPLC. In the instance 
of the Na'-dependent EAATs, the electrogenic nature of the uptake system has allowed 
this limitation to be overcome, as substrate-induced currents can be quantified 
electrophysiologically (Wadice et al., 1995). Unfortunately in this regard, system x̂  
appears to be electroneutral. To avoid these labor-intensive alternatives, we identified 
putative substrates of system x̂  using an approach pioneered by Nicholls and coworkers 
(Nicholls et al., 1987) that allows the efflux of L-glutamate from cells to be followed in 
real time by coupling its metabolism by glutamate dehydrogenase to the fluorometric 
detection of NADPH.
While admittedly semi-quantitative, this approach served well to demonstrate that 
the panel of identified inhibitors included both alternative substrates and non-substrate 
inhibitors, as well as highlight a number of interesting relationships that distinguish 
compounds that only bind to the substrate site on the transporter (and thereby act as 
competitive inhibitors) from those that bind and can be translocated. For exanq)le, the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
31
results demonstrate that conformational restriction does not by itself necessarily produce 
non-substrates. Thus, ibotenic acid exhibited similar activi^ to the endogenous substrate 
L-cystine, while the acyclic analogue L-serine-O-sulphate proved only about half as 
active. Although considerably less active than ibotenate, two closely related 
conformationally restricted analogues, 4d)romohomoibotenate and L-quisqualate, also 
proved capable of acting as substrates. In addition to illustrating that small structural 
changes can substantially influence substrate activity, the demonstration that quisqualate 
can directly exchange for intracellular L-glutamate through system is consistent with 
previous HPLC data demonstrating uptake in hippocampal slices and its proposed role in 
“quisqualate sensitization” (Chase et al., 2001). Interestingly, those compounds that 
proved to be the most potent competitive inhibitors (e.g. L-quisqualate and 4-S-CPG) 
also proved to be the least active as substrates, suggesting that distinct structural features 
may control binding and translocation. More specifically, the inhibitors exhibiting the 
highest affinities may be effectively interacting with domains on the transporter that 
promote binding, but preclude the actual translocation of the amino acid. Future studies 
will be aimed using the pharmacological profile generated in the present study to increase 
the library of active compounds, constructing pharmacophore models for both binding 
and transport, as well as develop functional probes with which to elucidate the role of 
system x̂  in antioxidant protection and excitotoxicity.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
32
Figure 3.1. Schematic representation of the glutamate dehydrogenase (GDH) 
fluorometric assay.
GyWne 370 nm ^m:45Qnfn
N «3P+— ^ ? r ^
<%-IWogluWWe
Efflux of Eglutamate from cells via system x, is quantised by measuring the level of 
NADPH fluorescence generated by the metabolism of released L-glutamate by GDH.
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Table 3.1. Ionic dependence of L-cystine induced L-glutamate efflux in SNB-19 
glioma cells.
Experiment Ionic Constitnent Rate of L-glutamate eHInx 
(nmol/min/mg protein)
Total NaVa- 0.61 ±0.06 (3)
Cl Free NaVGluconate 0.46 ±0.02 (3)
Na'' Free ChohneYCl 1.03 ±0.15 (7)
NaVCl Free Sucrose 0.42 ±0.02 (3)
Efflux of L-glutamate stimulated by L-cystine (250 mM) from SNB-19 cells was 
determined as described in the methods in the presence or absence of the indicated ions. 
Values are reported as mean ± S.E.M., (n).
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Table 3.2. Competitive inhibitors of system exhibit a wide range of substrate 
activities as determined by hetero-exchange with intracellular L-glutamate in SNB-19 
glioma cells.
Compound [liM] L-Glntamate 
Uptake Rate 
(pmol/min*mg)
%
Inhibition
L-GIutamate 
Exchange Rate 
(nmol/min*mg)
% of
Cystine
L-cystine 500 79 ± 13 (6) 88 1.40 ±0.06 (12) 100 ±4
Ibotenate 300 98 ±11 (6) 86 1.49 ±0.06 (3) 106±4
L-Homocysteate 350 57 ±11 (6) 92 0.84 ± 0.04 (3) 60±5
(RS)-4-Bromo-
homoibotenate
200 21 ± 3 (6) 97 0.77 ± 0.03 (3) 55 ±5
L-Serine-O-sulphate 250 89 ± 18 (6) 87 0.72 ±0.05 (3) 51 ±7
L-Quisqualate 50 115 ±18 (6) 83 0.49 ±0.05 (6) 35± 10
(S)-4-Carboxy-
phenylglycine
50 129±11(6) 81 0.21 ±0.02(3) 15 ±10
The substrate-induced efflux of L-glutamate from SNB-19 glioma cells by previously 
identified competitive inhibitors was determined using the glutamate dehydrogenase- 
based fluorometric assay described in AfgfAodis. Compounds were tested at 
concentrations that produced similar levels of inhibition (88 ± 2% of Control levels) so 
that substrate activities were determined at comparable levels of transporter occupancy. 
Control uptake for 100 pM L- pH]-glutamate was 680 ± 49 pmol/min mg protein (n = 
17). Values are reported as mean ± S.E.M. (n). The rates of L-glutamate exchange have 
been corrected for background efflux and are reported as mean ± S.E.M. (n).
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Figure 3^. Fluorescence standard curve.
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A) Generation of a fluorescence standard curve in the presence of NADP^ (Im M ) 0 sec, 
GDH (33U) 60 sec, and coverslips with sequential 4 nmol injections of L-glutamate 
every 200 sec. (B) L-Glutamate standard curve derived from fluorescence data (A).
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36
3 0
2 5
1 5
Ô1 0
5
0
5 0 0 1000  
Time (s)
1500 2000
B
0
@4 0 o
o
2 0
0
0
5 0 0 1 000  
Time (s)
1500 2000
(A) Baseline L-glutamate efflux Aom SNB-19 cells in the presence of NADF^ (Im M ) 0 
sec, GDH (33 U) 60 sec, with an addition of 0.5% Triton X-100 at 1500 sec. (B) L- 
CyStine induced L-glutamate efflux in SNB-19 glioma cells stimulated by the addition of 
500 |iM  L-cystine at 600 sec.
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Figure 3.4. 4-S-CPG acts as a non-substrate inWbitor of system .
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Representative traces are overlayed demonstrating the ability of L-cystine but not 4-S- 
carboxyphenylglycine to exchange with L-glutamate. Consistent with their action at the 
same transporter, 4-S-CPG blocked L-cystine induced exchange when both were 
included in the assay. In all experiments exchange was measured in Na^-free HBHS 
buffer containing NADP^ (1 mM), GDH (33 U), in presence or absence of L-cystine (500 
p ^ , and/or 4-S-CPG (50 pM).
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Chapter 4: The Lathy/w Excitotoxim p-N-Oxalyl-L-a,P-Diammopropionic Acid 
(P-L-ODAP) is an Effective Substrate of the L-GIdtamate/L-Cystine Exchanger 
System x ,.
Introduction:
p-N-Oxalyl-L-a,p-diamino-propionic acid (p L-ODAP) (also know as L-BOAA, 
p-N-Oxalyl amino-L-alanine), found in the seeds of sativus, is a dicarboxylic
amino acid thought to be an active agent in human lathyrism (Rao, 1964). p-L-ODAP 
and the excitatory amino acid L-glutamate share similar chemical structures. With a pKa 
of 1.95 and 2.95 on the a  and distal carboxyl groups, respectively, and a pKa of 9.25 on 
the a  amino moiety, p-L-ODAP is an anionic species with a negative one charge at 
physiological pH (Rao, 1964). In contrast, p-L-ODAP substitutes an N-oxalyl amide 
group at the gamma position and is one carbon longer than L-glutamate. Excessive 
consumption of chick peas containing this excitatory amino acid agonist is believed to 
cause spastic, irreversible paralysis of the lower limbs (for review see Ludolph etal., 
1987). Males are predominately affected (3:1) following a 2 to 4 month diet containing 
50-200 gram/day portions of the chickling pea with a p-L-ODAP content of 1-2%. 
vivo studies with macaque monkeys revealed that these primates develop lower limb 
paralysis following a one month diet enriched with p-L-ODAP (Spencer et al., 1986). 
Discontinuation of p-L-ODAP consumption led to stabilized paralysis with no further 
chronic progression. Injection of p-L-ODAP into rat lumbar cerebrospinal fluid causes 
distended myelin sheaths with occasional axonal loss in spinal cord sections. This is in 
contrast with its isomer a-L-ODAP which proved to be non-toxic (Chase etal., 1985).
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Other in vivo work using mammal models demonstrated that intraperitoneal and oral 
administration of p-L-ODAP to adult mice led to neurological damage following CNS 
accumulation (Mehta, 1979). In the primary cortex of Aeely moving rats, p-L-ODAP 
caused an increase in aspartate that was inhibited by a non-NMDA antagonist and a 
glutamate increase that was resistant to inhibiton by the non-NMDA antagonist (La Bella 
et al., 2000). Other work in freely moving rats revealed that L-BOAA increased the 
production of gangliosides in the hippocampus and decreased production in the olfactory 
bulbs (Valdes-Gonzalez et al., 2001).
Electrophysiological studies in cultured fetal mouse spinal neurons, demonstrated 
p-L-ODAP to be a non-NMDA agonist since D-AP5 could not block its activity 
(MacDonald and Morris, 1984). Later studies in synaptic plasma membranes 
demonstrated p-L-ODAP to act potently at quisqualate metabotropic receptors with an 
10%= 1.3 pM and less potently at the kainate receptor (ICa,= 17 pM) (Bridges et al, 
1989). In guinea pig hippocampal synaptosomes, p-L-ODAP has been fotmd to enhance 
L-glutamate release (Gannon, 1989). Using ion-selective microelectrodes, p-L-ODAP 
was found to increase Na  ̂influx and efflux, with no effect on intracellular Câ  ̂levels
in Retzius nerve cells (Cemerikic et al., 2001). In addition to its neurotoxic effects, p-L- 
ODAP has been shown to be dose dependently toxic to primary cultures of neonatal rat 
astrocytes, causing vacuole formation, swelling, and cellular lysis (Bridges et al, 1991).
The interaction of p-L-ODAP with different enzymes has also been reported. In 
rat primary astrocyte cultures, p-L-ODAP administration over 24 hours increased 
glutamine synthetase activity to 150% of control (Miller et al., 1993). In male mouse 
brain slices, p-L-ODAP has been shown to inhibit NADH ubiquinone-1 oxidoreductase
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by thiol modiAcaüon (Sriram et al., 1998). p-L-ODAP was also shown to be a 
noncompetitive inhibitor with respect to tyrosine for the liver enzyme tyrosine 
aminotransferase in white mice (Vardhan et al.rl997).
P-N-oxalylamino-L-alanine was found to induce cell death in VSC 4.1 
motoneuron hybrid cells and immature cortical neurons (La Bella et al., 1996; Murphy et 
al., 1990). L-Glutanmte, L-quisqualate, and BOAA-mediated cell death was attenuated in 
the presence of 1 mM cysteine in the study by La Bella et al., (1996), while Murphy et 
al., (1990) reported that p^S]cystine uptake was inhibited by BOAA. Along with the 
other previous sites of action, these results indicate BOAA may be interacting directly 
with system x^, System x̂  is a heteromeric L-cystine/L-glutamate exchanger which 
brings L-cystine into the cell in exchange for L-glutamate. L-Cystine uptake through this 
transporter is the rate limiting step in GSH biosynthesis in human Abroblasts (Bannai, 
1982).
In the present study, we use selective pH]-L-glutamate uptake assays in SNB-19 
glioma cells to delineate the action of p-L-ODAP at system x^. Inhibition of chloride- 
dependent L-glutamate uptake by p-L-ODAP and not by its biochemically inactive 
isomers and analogues was fotmd. Kinetic analysis elucidated p-L-ODAP to be a 
competitive inhibitor with a K,= 99 ± 12 piM (3). In conjunction, fluorometric assays 
indirectly meastmng L-glutamate efflux via system x̂  in SNB-19 cells are used to 
determine the ability of p-L-ODAP to serve as a substrate, partial substrate, or a non­
transportable inhibitor. We report that p-L-ODAP is a competitive inhibitor of system x/ 
that can serve as a substrate eliciting an L-glutamate efflux that is attenuated in the 
presence of the non-transportable inhibitor 4-S-carboxyphenylglycine.
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Results:
P-L-ODAP and N-oxalyl-diamino-dicarboxylic acid analogues were tested for the 
ability to interact with system by measuring their effect on Cl -dependent L-glutamate 
uptake in SNB-19 cells. Reported in Table 4.1, p-L-ODAP (500 pM) produced 
approximately 81% inhibition in Cl -dependent L-glutamate uptake. This amount of 
inhibition is similar to that produced by competitive system x̂  inhibitors L-quisqualate 
and L-cyStine (500 |iM). The nontransportable inhibitor 4-S-CPG (500 pM) completely 
inhibited system The ability of p-D-ODAP and the a  isomers to inhibit Cl - 
dependent L-glutamate uptake was much less pronounced and illustrate an enantiomer 
specific interaction of P-L-ODAP with system x̂ '. The ODAB homologues and BMAA 
were also found to be relatively inactive as inhibitors. The exact means of this inhibition 
was explored in kinetic studies of Cl -dependent L-glutamate uptake presented in Figure 
4.1. P-L-ODAP, at concentrations of 60,180, and 300 pM, decreased Cl -dependent L- 
glutamate uptake in a competitive fashion. As illustrated by the Lineweaver-Burk plot, 
Vgua values stayed the same while ^  values increased with increasing concentrations 
of P-L-ODAP. For the experiment represented in Rgure 4.1, and values of 96 ± 
3 and 1029 ± 16 pmols/min mg protein were foimd which are consistent with previously 
reported kinetic constants found for Cl -dependent uptake in the SNB-19 cells (mean ± 
SEM, n = 4) for L-glutamate of 111 ± 10 pM and 1410 ± 72 pmol/min mg protein, 
respectively. A K, was determined by generating a plot of as a function of [I] and 
is represented by the inset in Figure 4.1. The P-L-ODAP/Cl -dependent L-glutamate
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transporter dissociation constant determined for three separate experiments was 99 ± 12 
pM.
The fluorometric assay was employed to further elucidate the interaction of P-L- 
ODAP with the Cl -dependent L-glutamate transporter. Figure 4 2  illustrates an overlay 
of both L-cysdne (250 pM) and P-L-ODAP (250 pM) induced L-glutamate efflux rates in 
SNB-19 cells grown on coverslips. Generation of a standard curve by identical means as 
represented in Rgure 3.2 allowed the L-glutamate efflux rates to be quantified under each 
condition. Following correction for nonspecific L-glutamate efflux, an average of three 
separate experiments yielded L-cystine- (250 pM) and P-L-ODAP- (250 pM) induced 
chloride-dependent l-glutamate efflux rates of 1.040 ± 0.11(12) and 1.170 ± 0.05 (3), 
respectively. At equal concentrations, P-L-ODAP induced a similar L-glutamate efflux 
rate as that elicited by the endogenous system x̂  substrate L-cystine.
In Rgure 4.3, use of the non-transportable inhibitor 4-S-CPG was used to clarify 
whether chloride-dependent P-L-ODAP induced L-glutamate efflux was mediated 
through system x, . Upon co-injection of 4-S-CPG with P-L-ODAP and 4-S-CPG with 
L-cystine, L-glutamate efflux declined as represented pictorially in panels A and B. 
SpeciBc L-cystine- (500 pM) and P-L-ODAP- (370 pM) induced L-glutamate efflux 
rates were 1.34 ± 0.07 (15) and 1.20 ± 0.04 (4). Specific L-glutamate efflux rates 
declined to 0.36 ± 0.08 (3) for L-cystine (500 pM) + 4-S-CPG (50 pM) and 0.45 ± 0.04 
(5) in the presence of p-L-ODAP (370 pM) + 4-S-CPG (50 pM).
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Discussion:
In the present study we directly examine the action of P-L-ODAP at the Cl - 
dependent L-glutamate transporter system x^. We have recently published findings that 
the Grade IV  human glioblastoma SNB-19 contains two xCT transcripts; xCTa and xCTb 
and demonstrated a Cl -dependent L-glutamate uptake activity with a of 1410 ± 72 
pmol/min mg protein (n = 4) (Patel et al., 2004). The combination of pharmacological 
and kinetic data directly show p-L-ODAP to be a competitive inhibitor at system x̂  . 
Further elucidation in the human glioblastoma cell line revealed the ability of P-L-ODAP 
to elicit a Cl -dependent L-glutamate efflux. This EAA analogue (250 pM) induced an 
efflux rate of L-glutamate that was similar to that produced by the system x,. endogenous 
substrate L-cystine (250 pM). This evidence, along with attenuation of substrate- 
induced L-glutamate exodus in the presence of the system x, non-transportable inhibitor 
4-S-CPG, points to the ability of P-L-ODAP to serve as a system x,. substrate. Thus, we 
show for the first time the ability of P-L-ODAP to be transported into the cell via system 
Xc'.
The activity of P-L-ODAP at the Cl -dependent L-glutamate transporter appears 
to be enantiomer specific, with P-D-ODAP only partially inhibiting transport. An 
extensive pharmacological screen of N-oxalyl-diamino-dicarboxylie acid analogues at the 
Cl -dependent L-glutamate transporter directly shows the specificity of P-L-ODAP at 
system x^. Longer chain y homologues and the EAA analogue BMAA proved to be poor 
inhibitors. The shorter length a-L-ODAP was also relatively inactive at system x ,.
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Interestingly, by boiling the chickling pea during meal preparation, some P-L-ODAP is 
converted to its a-isomer, which appears to be non-neurotoxic (Chase et al., 1985).
It is of interest to relate the ability of P-L-ODAP to serve as a system x̂  inhibitor 
and its ability to mediate toxicity in immature cortical neurons and hybrid motoneuron 
cells (La Bella et al., 1996; Murphy et al., 1990). In the study by Murphy et al., (1990), 
inhibition of cystine uptake by BOAA produced a high percentage of neuron death. In 
findings by La Bella et al., (1996), apoptotic cell death followed incubation of ventral 
spinal cord 4.1 cells with P-N-oxalylamino-L-alanine and co-incubaüon of BOAA with 
cysteine prevented this outcome. In both studies, incubation with the antioxidant a- 
tocopherol attenuated cell death related to cystine transport inhibition. The mechanism of 
P-N-oxalylamino-L-alanine toxicity in these two studies is consistent with inhibition of 
the cystine/glutamate antiporter system x, leading to depleted intracellular GSH levels 
with subsequent oxidative damage and cell death.
Studies in male mouse brain slices show L-BOAA induced oxidation of thiols as 
the reason behind lost mitochondrial complex I activity (Sriram et al., 1998). L-BOAA 
induced complex I inhibition in motor cortex and lumbosacral slices was reversed by 
incubation with the reducing agent dithiothreitol. In the lumbosacral area a significant 
reduction in GSH followed L-BOAA mediated-complex I inhibition. These m vivo 
results were reversed with the addition of the AMPA receptor antagonist NBQX and the 
antioxidant a-lipoic acid. Although L-BOAA may be causing oxidative inhibition of 
complex I activity through non-NMDA receptor activation, studies in isolated 
mitochondria show L-BOAA to directly inhibit complex I NADH-dehydrogenase activity 
without first serving as a EAA receptor agonist (Pai et al., 1993). /n vivo, male mice
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studies revealed L-BOAA induced inhibition of complex I activity in motor cortex and 
lumbosacral areas is reversed following upregulation of glutaredoxin (Kenchappa et al., 
2002). Following a single dose of L-BOAA insult, GSH levels drop and pretreatment 
with thioltransferase antisense oligonucleotides prevented a reversal of L-BOAA 
mediated inhibition of complex I. In order for thioltransferase to activate complex I 
activity following L-BOAA mediated insult, GSH levels need to be increased. Following 
a single dose of L-BOAA, GSH levels in the motor cortex and lumbosacral cord 
decreased. Levels returned to control levels in the motor cortex but remained attenuated 
in the lumbosacral cord 24 hours post insult. Under the same conditions, y-glutamyl 
cysteine synthetase activity was elevated above control levels in the motor cortex but 
arrived back to control levels in the lumbosacral cord 24 hours post L-BOAA insult 
(Kenchappa et al., 2003).
Œiotoxicity of EAA analogues p-L-ODAP, L-a-aminoadipate, L-homocysteate, 
and L-serine-O-sulphate, but to a much lesser extent by enantiomers, p-D-ODAP, D-a- 
aminoadipate, and D-homocystine, was shown in neonatal Type I astrocytes (Bridges et 
al., 1991; Bridges et al., 1992). The lack of action of ionotropic L-glutamate agonists 
NMDA, KA, and AMPA indicate the cause of gUotoxicity was not by EAA ionotropic 
receptor stimulation. Nuclear swelling with subsequent cellular lysis characterize the 
toxic path that was absent in the presence of endogenous amino acids L-glutamate and L- 
aspartate. These transmitters caused only nuclear abnormalities followed by the return to 
normal cellular morphology 36-48 hours later. p-L-ODAP caused large vacuole 
formation in the astrocytes with similar physical changes found earlier in neurons (Nunn 
et a l., 1987).
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In addition to showing that p-L-ODAP is a system x,. substrate we have shown L- 
homocysteate, L-serine-O-sulphate, and L-a-aminoadipate to be partial substrates at the 
Cl-dependent L-glutamate transporter. It has been proposed that L-a-aminoadipate 
serves as a transport system substrate before mediating its gliotoxic actions following 
intracellular accumulation (Huck et al., 1984). This action appears to be enantiomer 
specific and the metabolism of L-a-aminoadipate minimal. Our studies show the action 
of P-L-ODAP at system x,. is also enantiomer specific and others show intracellular 
metabolism of the dicarboxylic diamino acid to be negligible (Mehta et al., 1979; Jyothi 
et al., 1998)
These findings represent the first, in-depth pharmacological and kinetic 
characteristics of the interaction of P-L-ODAP with system x^. Whether or not P-L- 
ODAP- induced pathology in newolathyrism is through direct stimulation of non-NMDA 
receptors, its interaction with the chloride-dependent L-glutamate transporter is of 
interest. Synaptic clearance and intracellular accmnulation of P-L-ODAP by system x/ 
may contribute to neurolathyrism in different ways. First, p-L-ODAP can be removed 
via transport and its presence in the synapse abbreviated around areas of high system x, 
expression. An in .rim hybridization study in mouse brain revealed xCT and 4F2hc 
mRNA distribution in the meninges, hypothalamus, and cells surrounding the cerebral 
third ventricle (Sato et al., 2002). Immunocytochemical studies using viable antibodies 
directed against the system x̂  light subunit xCT are still needed to further elucidate these 
findings. Secondly, while P-L-ODAP is occupying the system x<. exchanger, cystine 
transport by this transporter is attenuated. Cells vulnerable to oxidative damage and 
dependent on GSH maintenace through this rate limiting process are susceptible to
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apoptotic and necrotic cell death, /n vitro studies show VSC motoneuron hybrid cells are 
dependent on L-cystine uptake by system whereas primary astrocytes are not (LaBella 
et al., 1996; Bridges et al., 1991). Thirdly, due to the lack of P-L-ODAP metabolism, 
high levels of intracellular accumulation may occur. This could contribute to cell death 
in the CNS in two ways. Firstly, intracellular P-L-ODAP may reach high enough levels 
to heteroexchange with extracellular system x, substrates. During this process, p-L- 
ODAP would be transported out of the cell and released back into the synapse. A similar 
phenonmenon, termed the "quisqualate effect," occurs using the neurotoxic and system 
Xg substrate L-quisqualate (Chase et al., 2001). In the course of quisqualate sensitization, 
system x̂  appears to first remove the neurotoxin from the synapse and initially protect 
neurons from excitotoxic damage. Following intracellular accumulation and lack of 
metabolism, L-quisqualate may heteroexchange with extracellular substrates through 
system x̂  and once again be released into the synapse making neurons susceptible to 
damage or death through overstimulation of ionotropic L-glutamate receptors. Lastly, P- 
L-ODAP has been shown to directly interact with the enzymes glutamine synthetase, 
tyrosine aminotransferase, and NADH dehydrogenase (Miller et al., 1993; Vardhan-Shasi 
et al., 1997; and Pai et al., 1993). High intracellular levels of this EAA analogue may 
inhibit one or all of these enzymes and cause cell death. The summation of these affects 
may play a role in the onset and progression of neurolathyri^.
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Table 4.1. Activity of P-L-ODAP and selected isomers at the Cl -dependent L-glutamate 
transporter.
Compound [pM] % Control
Control - 100±6 (23)
B-L-ODAP 500 19±1 (3)
B-D-ODAP 500 77±3 (3)
a-L-ODAP 500 95±3 (3)
y-L-ODAB 500 65±3 (3)
y-D-ODAB 500 70±3 (3)
BMAA 500 88±2 (3)
L-Quisqualate 500 19±1 (3)
4-S-CPG 500 0±0(3)
L-cystine 500 11±1(6)
Uptake of 100 pM L-glutamate under chloride-dependent conditions in SNB-19 cells was 
determined as described in Methods. The rates of L-glutamate uptake have been 
corrected for non-specific uptake and are reported as mean ± S.E.M. (n).
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Figure 4.1. Competitive inhibition of high-affinity, chloride-dependent, [^H]-L-glutamate 
uptake into SNB-19 glioma cells by P-L-ODAP.
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Representative Lineweaver-Burk plot demonstrating (he competitive inhibition of [^H]-L 
glutamate uptake into SNB-19 glioma cells by p-L-ODAP. The inset shows a replot of 
V.T [P-L-ODAP]. The plots shown were generated using the k-cat kinetic program 
(BioMetallics Inc, Princeton NJ) with weighting based on constant relative error, and 
yielded values of: Km=96 ± 3 pM, 1029 ± 16 pmol/min mg protein, and = 78 ± 
12 pM (K,.= 99 ± 12 pM (3)).
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Figure 42. L-cysüne- and P-L-ODAP- induced l-glutamate efflux in SNB-19 cells.
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Overlying fluorometric plots representing L-cystine- and P-L-ODAP- induced L- 
glutamate efflux rates. Equal concentrations of L-cystine and P-L-ODAP (250 |iM) were 
injected at 6(X) seconds followed by 0.5% Triton X-KX) at 15(X) seconds. Induced L- 
glutamate efflux rates for the representative L-cystine and P-L-ODAP plots are 0.935 
and 1.097 nmols/min mg respectively. Non-specific L-glutamate efflux for the 
representative trace is 0.079 nmol/min mg protein.
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Figure 4.3. Attenuation of L-cystine- and P-L-ODAP- induced L-glutamate efflux rates 
by 4-S-CPG.
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(A) Representative traces are overlayed demonstrating 4-S-CPG (50 ^M) attenuation of 
L-cystine- (500 pM) induced Lrglutamate efflux. Specific rates for the representative 
graphs are: L-cystine (500 pM) = 1.25 nmols/min mg protein, L-cystine (500 pM) + 4-S- 
CPG (50 pM) = 0.51 nmols/min mg protein, 4-S-CPG (50 pM) = 0.00 nmols/min mg 
protein, and baseline = 0.07nmols/min mg protein. (B) 4-S-CPG (50 pM) attenuation of 
P-L-ODAP- (370 pM) induced L-glutamate efflux. Specific rates for the representative 
graphs are: P-L-ODAP (370 pM) = 1.29 nmols/min mg protein, P-L-ODAP (370 pM) + 
4-S-CPG (50 pM) = 0.58 nmols/min mg protein, 4-S-CPG (50 pM) = 0.00 nmols/min mg 
protein, and baseline = 0.07nmols/min mg pilfein. Specific rates for at least three 
separate experiments are: L-cystine (500 pM) = 1.34 ± 0.07 (15) nmols/min-mg protein, 
P-L-ODAP (370 pM) = 1.20 ± 0.04 nmols/min mg protein (4), 4-S-CPG (50 pM) = 0.17 
± 0.05 nmols/min-mg protein (7), L-cystine (500 pM) + 4-S-CPG (50 pM) = 0.36 ± 0.08 
nmols/min-mg protein (3), P-L-ODAP (370 pM) + 4-S-CPG (50 pM) = 0.45 ± 0.04 
nmols/min-mg protein (5), Non-specific rates = 0.18 ± 0.02 nmols/min-mg protein (28). 
In all experiments exchange was measured in Na^-free HBHS buffer containing NADP^ 
(Im M ) and GDH (33U).
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Chapter 5: Evaluating the Relationship Between System x. Activity and 
Maintenance of GSH Levels in Human Glioma Cells.
Introduction:
Glutamate transport in the CNS is divided into two high-afRnity systems: the Nâ  
-dependent transport family system and the Cl -dependent glutamate/cystine 
exchanger system x^. We have studied total L-glutamate uptake in human astrocytoma 
cell lines and found that a higher percentage of L-glutamate uptake was mediated through 
the Cl -dependent L-glutamate transporter than the Na^-dependent L-glutamate transport 
systems. This increased activity of Cl -dependent L-glutamate transport is consistent 
with that found in rat and human cells of glioma origin (Cho et al., 1990; Ye et al., 1999). 
This increased activity of L-glutamate uptake is consistent with an increased expression 
of system x^. This transporter is a cystine/glutamate obligatory exchanger. It is non- 
electrogenic and under normal physiological conditions uses a higher intracellular L- 
glutamate concentration to drive the import of cystine into the cell with subsequent efOux 
of L-glutamate from the cell (Bannai, 1982). It is a heteromeric transport system 
composed of two subunits: 4F2hc and xCT (Sato, 1999). The regulatory subunit, 4F2hc, 
is a glycoprotein containing one transmembrane domain with the light chain, xCT, 
containing twelve putative domains. Upon oxidative stress, sytem x,. expression is 
upregulated (Bannai, 1984). In the presence of diethyl maleate, an electrophilic agent, 
xCT mRNA levels were upregulated in rat and mouse endothelial cells with no change in 
4P2hc mRNA levels (Tomi et al., 2002; Hosoya et al., 2002).
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The relationship between Cl -dependent L-glntamate/cystine transport activity and 
glutathione (GSH) synthesis is of particular interest. GSH is the major intracellular thiol 
in mammalian cells and a key intermediate in a wide range of biochemical processes 
(Cooper and Kristal, 1997; Meister, 1995; Meister, 1983). GSH directly conjugates with 
various electrophilic drugs and assists in their metabolism and is a protectant from 
oxidative damage by acting directly or enzymatically in the neutralization of reactive 
oxygen species, free radicals, and electrophiles (Meister, 1991; Shen et al., 1997). 
Glutamate, cysteine, and glycine are linked in two separate energy dependent 
enzymatically coupled steps to synthesize GSH (Griffith and Meister, 1979). Of the 
three amino acids, intracellular GSH levels appear most dependent upon the availability 
of L-cysteine. Transport of extracellular L-cystine or L-cysteine is the predominant 
means of providing L-cysteine for GSH synthesis. Due to oxidative conditions in the 
extracellular environment, cystine appears to be the primary sulfhydryl amino acid in 
culture media, plasma, and CSF (Bannai and Ishii, 1982; Cho and Bannai, 1990; Kranich 
et al., 1998).
In certain glioma and neuroblastoma cell lines, maintenance of total intracellular 
GSH levels and cell viability are dependent on L-cystine transport by system x^. In the 
N18-RE-105 retinoblastoma cells, glutamate and the system x,. inhibitors quisqualate and 
ibotenate markedly inhibited L-cystine uptake. Decreased intracellular GSH levels were 
subsequently observed, followed by oxidative cell death. These effects were not 
mimicked by other EAA ionotropic and metabotropic receptor agonists (Murphy et al., 
1989). In the rat glioma cell line, C6, intracellular GSH levels were depleted in an
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environment with high L-glntamate concentrations and reversed by the addition of 
increased L-cystine (Cho and Bannai, 1990).
Using four human astrocytoma/glioblastoma cell lines grown in similar media and 
conditions, we explore the relationship between Cl-dependent L-glutamate uptake 
activity and maintenance of intracellular GSH levels through system x,. -mediated L- 
cyStine uptake. Our goal is to Rrst identify groups of glioma cell lines that exhibit a 
range of Cl -dependent L-glutamate uptake activity and determine total intracellular GSH 
levels (GSH + GSSG) in these cells when grown under identical conditions. Our kinetic 
findings showed an approximate five fold range in system x,. activity among these cells. 
The SNB-19 cell line, which expressed the highest Cl -dependent L-glutamate uptake 
activity, also exhibited the highest total intracellular GSH concentration. All four tumor 
cell lines had very similar relative rates of GSH turnover based upon inhibition of 
glutathione synthesis with the y-glutamylcysteine synthetase inhibitor L-buthionine- 
[SR]-sulfoximine. However, GSH levels were not equally decreased by the system x, 
inhibitor, 4-S-carboxyphenylglycine. Thus, the GSH pools in all of the tumor cell lines 
may not be similarly dependent on L-cystine uptake by system x^, but may express 
alternative transport systems to provide the GSH rate limiting precursors L-cystine or L- 
cysteine.
Results:
Detailed kinetic analyses quantifying Cl -dependent [^H]-L-glutamate transport 
activity (equimolar substitution of Na  ̂with choline) in four glioma cell lines were
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performed and corrected for non-speciRc uptake by substracting the amount of 
glutamate accumulated at 4 °C. Lineweaver-Burk plots and associated kinetic parameters 
were estimated by computer analysis using the k.cat kinetic program (BioMetallics Inc.) 
with weighting based on constant relative error and reported in Table 5.1 (mean ± SEM, 
n = 4). We first reported and values for Cl -dependent [^H]-L-glutamate 
transport in SNB-19 cells in a previous study (Patel etal., 2004). A student t-test 
revealed a statistically higher (p < 0.01) value for SNB-19 cells relative to the others 
and a statistically higher (p < 0.01) for U-373 #elative to the three other tumor cell 
lines. Vgug values amongst the U-373, SW-1088, and CCF-STTGl cell lines show slight 
variances, but were not statistically different (p > 0.05). A comparison of SNB-19, SW- 
1088, and CCF-STTGl Kg, values also revealed no difference (p > 0.05).
The DTNB-based recycling assay of Tietze (1969) with modifications by Griffith 
(1980) and Anderson (1985) was used to assay total intracellular GSH (GSH + GSSG) 
concentrations in the four human glioma cell lines. Cells at 90 to 95% confluency and 
grown under similar media and conditions were harvested and total intracellular GSH 
levels determined. Values are reported in Figure 5.1 as mean (nmols/mg protein) ± SEM 
(n). Total intracellular GSH levels in SNB-19 cells are, 67 ± 3 (22), a value statistically 
higher (p < 0.01) than total GSH levels detected in the other three cell lines. The CCF- 
STTGl cells exhibit the second highest intracellular GSH levels of 55 ± 3 (19), and are 
statistically different (p < 0.01) from the SW-1088 = 38 ± 2  (19) and U-373 = 34 ± 2 (20). 
No difference was fotmd between total intracellular GSH levels in the SW-1088 and U- 
373 cells.
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The effect of increased extracellular levels of rate limiting precursors L-cystine 
(250 and 500 ;/M ) and L-cysteine (500 /fM  and 1 mM) on total intracellular GSH levels 
in four human glioma cell lines was evaluated and presented in Rgure 5.2 as mean 
(nmols/mg protein) ± SEM (n). Media changes were performed every three to four days. 
Control L-cystine and L-cysteine concentrations in the growth media on these days were 
100 and 125 /fM  respectively. At the beginning of the incubation period when cells were 
90 to 95% confluent, L-cystine or L-cysteine were added to designated wells without a 
media change and the cells were harvested 24 hours later. Neither concentration of L- 
cystine produced a statistical rise in total intracellular GSH levels while L-cysteine (500 
[ iM)  statistically raised SNB-19 levels (p < 0.01). This suggests that L-cystine was 
present in the media at a saturating level relative to GSH synthesis in the control 
conditions. The ability of L-cysteine (500 /fM ) to increase intracellular total GSH levels 
in the SNB-19 cells may indicate that the 125 ;^M concentration of this amino acid under 
control media conditions is not at a saturating concentration and intracellular GSH levels 
in this cell line may be effected by L-cysteine levels.
A time course study evaluating GSH turnover in the four cell lines using the y- 
glutamylcysteine synthetase inhibitor L-buthionine-[SR]-sulfoximine (500 /fM ) was 
performed. Values are reported in Figure 5.3 as mean % of control ± SEM. BSO 
irreversibly inhibits the enzyme y-glutamylcysteine synthetase. At the beginning of the 
incubadon period, BSO (500 ;<M) was added to designated wells without a media change 
and cells were harvested at the indicated time points. Following the 24 hour time course, 
total intracellular GSH levels were similarly reduced to approximately 10% of control in 
the SNB-19, CCF-STTGl, and U-373 cells. Levels were decreased statistically lower (p
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< 0.05) relative to the other three cell lines in the SW-1088 cells to approximately 5% of 
control.
The contribution of other amino acid transporters to the maintenance of total 
intracellular GSH levels was evaluated using inhibitors at concentrations estimated to 
inhibit transport by 80-90% estimated from literature values. The inhibitors included: 
system x, inhibitor 4-S-carboxyphenylglycine (4-S-CPG), system x̂ ĝ inhibitor L-trww- 
pyrrolidine-2,4-dicarboxylic acid (L-T-2,4 PDC), system ASC inhibitor L-N^-P- 
chlorophenyl-glutamine (L-N.,-PCP-G), and system L inhibitor 2-amino-2-norbomane- 
carboxylic acid (BCH). Values are shown as mean % of control ± SEM and are 
displayed in Figure 5.4. At the beginning of the incubation period when cells were 90- 
95% confluent, the transporter blockers were added to designated wells without a media 
change and cells were harvested following a 24 hour incubation period. In all four cell 
lines, 4-S-CPG significantly reduced total intracellular GSH levels relative to control (p < 
0.01). Interestingly, SNB-19 GSH levels following the 24 hour incubation period in the 
presence of 4-S-CPG (250 //M ) were stadsdcaUy greater than GSH levels in the three 
other cell lines under the samb conditions (p < 0.01). The other three transporter blockers 
had no significant effect on tot^ intracellular GSH levels.
In order to further elucidate the role of system x,, in the maintenace of total 
intracellular GSH levels in (he four human glioma cell lines, a time course study using 
the non-transportable inhibitor 4-S-CPG was performed. Values are reported in Figure 
5.5 as mean % of control ± SEM. At the beginning of the incubation period, 4-S-CPG 
was added to designated wells without a media change and cells were harvested at 2,6, 
12, and 24 hour time points. Following the 24 hour incubation period, total intracellular
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GSH levels in the SNB-19 cells incubated with 4-S-CPG were approximately 40% of
%
control. 4-S-CTG depleted total intracellular GSH levels in the CCF-STTGl and U-373 
to approximately 20% of control and levels in the SW-1088 to approximately 15% of 
control . Total SNB-19 intracellular GSH levels 24 hours post a 4-S-CPG (250 ;^M) 
incubation time were statistically higher (p < 0.01) than intracellular levels found in the 
other three cells following a 24 hour period in the presence of 4-S-CPG (250 ;^M). 
Following the same 24 hour incubation period with 4-S-CPG (250 /^M), SW-1088 total 
intracellular GSH levels were slightly lower than CCF-STTGl levels (p < 0.05). No other 
differences were found in total intracellular GSH levels between the cell lines following 
the 24 hour 4-S-CPG (250 ;<M) insult.
The ability of L-cysteine or L-cystine to rescue total intracellular GSH levels 
following system x̂  transporter- mediated inhibition with 4-S-carboxyphenylglycine is 
evaluated in Table 5.2. Values are represented as mean % of control ± SEM (n). Media 
changes were performed every three to four days. Control L-cystine and L-cysteine 
concentrations in the added growth media were 100 and 125 ;<M respectively. At the 
beginning of the incubation period, when cells were 90 to 95% confluent, 4-S-CPG and
4-S-CPG with the amino acids L-cysteine or L-cystine were added to designated wells 
without a media change to give a total maximal concentration for the compounds of that 
listed in the table. Total GSH levels in all four cell lines in the presence of L-cystine 
(500 ;<M) + 4-S-CPG (250 ;<M) were statistically higher (p < 0.01) than GSH levels found 
solely in the presence of 4-S-CPG. In the presence of L-cysteine (500 /fM ) + 4-S-CPG 
(250 /iM ), GSH levels were statistically higher (p < 0.05) in the SNB-19 cells relative to 
the total intracellular GSH levels found in the CCF-STTGl and SW-1088 under the same
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conditions. This once again illustrates that total intracellular GSH levels in the SNB-19 
cells may be effected by L-cysteine uptake.
In order to determine if total GSH levels in the SNB-19 cells can be further 
decreased, total intracellular GSH levels were measî pd in the presence of 4-S-CF*G in 
combination with other transporter blockers. Values are reported as mean % of control ± 
SEM and displayed in Figure 5.6. At the beginning of the 24 hour incubation period, 4-
S-CPG and 4-S-CPG with the amino acid transporter blockers: L-T-2,4 PDC, L-N^-PCP- 
G, or BCH were added to designated wells without a media change to give a total 
concentration of compounds as that listed in the inset. Total intracellular GSH levels 
were statistically less (p < 0.05) following a#4  hour incubation period in the presence of 
4-S-CPG + L-Ny-PCP-G relative to total GSH levels found solely in the presence of 4-S- 
CPG. When comparing the total intracellular GSH levels in the SNB-19 cells following 
the incubation period with 4-S-CPG + L-N^-PCP-G with total intracellular GSH levels in 
the other three cell lines following a 24 hour incubation with 4-S-CPG, there is no 
statistical difference in reduced total GSH levels (p < 0.05).
Discussion:
The system transporter initially characterized on human fibroblasts is a Cl - 
dependent, Na^-independent electroneutral exchanger of L-cystine and L-glutamate 
(Bannai and Kitamura, 1980; Bannai, 1986). Composed of two subunits, xCT and 4F2hc, 
this transport protein is a heteromeric exchanger belonging to the glycoprotein-associated 
amino acid transporter (gpaAT) family (Verrey et al., 2000). Cl -dependent uptake of
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[^H]-glutamate is a marker of system x, activity and was used by our lab to elucidate the 
kinetic and pharmacological properties of this uptake system in two CNS-derived tumor 
cell lines, LRM-55 and SNB-19 (Patel, 2004). In this study we found the Group I 
metabotropic receptor antagonist, 4-S-carboxyphenylglycine (4-S-CPG) to be a potent 
competitive inhibitor and non-transportable substrate of the cystine/glutamate obligatory 
exchanger.
A series of human glioma cell lines grown in similar media and conditions were 
characterized for Cl -dependent L-[^H]-glutamate uptake to quantify system x̂  activity 
levels. By generating Lineweaver-Burk plots and obtaining the kinetic constants, and 
Vggg, some relative comparisons are made. An approximate Rve-fold range in system 
Xg activity is apparent between CCF-STTGl and SNB-19 cells by comparing values. 
These findings are consistent with other reports which show increased levels of Cl - 
dependent L-pH]-glutamate uptake in CNS-derived tumor cell lines relative to non- 
metastatic cells (Murphy et al., 1989; Waniewski and Martin, 1984). The exploitation of 
this biochemical difference may prove useful in future cancer therapy. Thus the 
physiological relevance between these varying levels of system x, activity and 
maintenance of intracellular GSH levels is of particular interest.
The DTNB-based recycling assay was used to determine total intracellular GSH 
(GSH +GSSG) concentrations in the four human glioma cell lines exhibiting a range of 
system x, activity. Cells at 90 to 95% confluency and grown under similar media and 
conditions were harvested and total intracellular GSH levels detected. The SNB-19 cell 
line, which expresses the highest Cl -dependent L-glutamate activity, has nearly double 
the concentration of total intracellular GSH levels (67 ± 3 (22)) relative to the SW-1088
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and U-373 cells (38 ± 2 (19) and 34 ± 2 (20) respectively) and a statistically greater (p < 
0.01) portion relative to CCF-STTGl levels (55 ± 3 (19)). Despite the range in total 
GSH values, these cell lines show similar percentage changes in the intracellular thiol 
when GSH biosynthesis is block^ with BSO (Figure 5.3).
We studied the contribution of the cystine/glutamate exchanger in maintaining 
intracellular GSH levels in the tumor cells by using the system x̂  non-transportable 
inhibitor 4-S-CPG and observing the changes in total intracellular GSH levels following a 
24 hour incubation period. 4-S-Carboxyphenylglycine statistically lowered (p < 0.01) 
total intracellular GSH levels in the four cell lines (Figure 5.4). A time course study with 
4-S-CPG revealed total intracellular GSH levels in the SNB-19 cell line to be least 
dependent upon system x̂  activity (Figure 5.5). Increasing intracellular GSH 
concentrations by supplementing L-cystine levels supported the notion that 4-S-CPG was 
causing its effect through inhibition of system x, (Table 5.2). Our findings indicate that 
maintenance of intracellular GSH levels in the CCF-STTGl, SW-1088, and U-373 is 
heavily dependent upon L-cystine uptake by system x^. To our surprise we found that 
even though the SNB-19 cells express the highest amotmts of system x, activity relative 
to the three other cell lines grown in a similar environment, total intracellular GSH levels 
in this glioblastoma cell line are the least dependent on L-cystine uptake by this 
transporter. This raises two interesting questions. The first is that in addition to L- 
cyStine uptake by system x^, what other transport system or systems may be providing 
precursors for GSH biosynthesis in the SNB-19 cells? We address this question 
experimentally. The second is what other physiological functions may system x, 
perform in vivo? This question is speculated upon below.
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System - mediated L-glutamate release from glioma cell lines in vifro is of 
particular interest. Over a twelve hour incubation period, the human astrocytoma cell 
line STTG-1 increased extracellular L-glutamate levels in culture from approximately 
100 pM to 400 pM, whereas primary astrocytes depleted L-glutamate levels from 92 to 1 
pM (Ye and Sontheimer, 1999). The STTG-1 release of L-glutamate was inhibited in a 
dose-dependent manner W  the system nontransportable inhibitor 4-S-CPG. 
Conversely, the endogenous system x, substrate L-cystine stimulated L-glutamate release 
in a dose- and time- dependent manner (Ye et al., 1999). In a glioma-neuronal coculture, 
disintegrated neurons were found 36 hours after coculture. Following an identical 
coculture trial in the presence of 4-S-CPG or the NMDA-specific inhibitor MK-801, 
neuronal cell death was prevented (Ye and Sontheimer, 1999). This suggests that the 
massive amounts of L-glutamate released through system x, may be a mode of glioma- 
mediated neurotoxicity (Sontheimer, 2003).
vitro and in vivo growth and migration studies were done on glioblastoma cells 
expressing Ca^-permeable AMPA receptors (Ishiuchi et al., 2002). fn vitro migration 
using the cell line CGNH-89 expressing Ca^ -̂permeable AMPA receptors was found 
while the CGNH-89 cells transgenically programmed to express Câ -̂ impermeable 
AMPA receptors showed retarded métastasés. Nude mice injected with the wild type and 
transgenic cells revealed similar findings (Ishiuchi et al., 2002). Thus, L-glutamate 
activation of these Ca^-permeable AMPA receptors appears to play a key role in the 
metastatic nature of these neoplastic cells. The origin of L-glutamate to induce this 
change is not known. Interestingly, in vivo findings in rats revealed that the main source 
of nonvesicular L-glutamate release into the nucleus accumbens is by system x̂  (Xi et 
al., 2002; Baker et al., 2003). These findings and others may indicate that human glioma 
cells can advantageously release copius amounts of L-glutamate through system x^. This 
l-glutamate may kill surrounding neurons opening up new niches for tumor cell growth
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while sending an autocrine message for tumor spread through activation of Câ *- 
permeable glutamate receptors (Sontheimer, 2003).
In addition to cystine transport by system , three other transport systems may 
contribute the rate limiting precursors, L-cysteine or L-cystine, for GSH synthesis. The 
Rrst, system L , has been shown to transport L-cysteine in mammalian cells (Bannai et 
al., 1984; Knickelbein et al., 1997). The second, system Xŷ g, is a Na -̂dependent L- 
glutamate transport family composed of rive subtypes EAAT 1-5 (Danbolt, 2001). In 
rat alveolar I I  cells and cultured astrocytes, system Xŷ  ̂ was shown to transport L-cystine 
(Knickelbein et al., 1997; Bender et al., 2000). Interestingly, studies have shown a 
reduction and mislocalization of sodium-dependent glutamate transporters in a series of 
human glioma cells (Ye et al., 1999). The third, system ASC, predominately transports 
the amino acids alanine, serine, and cysteine and belongs in the same solute carrier gene 
family (SLCl) as system Xŷ q (Kanai et al., 2001). The observed upregulation in system 
ASC expression in rat glioma and human neuroblastoma cells is of particular interest 
(Wasa et al., 2002; Dolinska et al., 2003).
In the four glioma cell lines, we studied the potential contribution that these three 
transport systems may play in GSH maintenace (Figure 5.4). No changes in GSH levels 
was observed. However, using die system ASC inhibitor L-Ny-PCP-G, we Rnd a 
statistically significant decline in SNB-19 GSH levels determined in the presence of L- 
Ny-PCP-G+4-S-CPG relative to GSH levels observed in the presence of 4-S-CPG (Figure 
5.6). We also show the significant rise in SNB-19 intracellular GSH levels in the 
presence of increased L-cysteine levels (Figure 5.2). In addition to L-cystine transport by
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system x ,, these Rndings may point to the ability of SNB-19 cells to provide the rate- 
limiting precursor L-cysteine by another transport system; system ASC.
System ASC is the predominant L-cysteine transporter found in a neuronal culture 
(Sagara et al., 1993). GSH levels in these cells could not be maintained by extracellular 
L-cystine but instead, only by gUal released L-cysteine (Sagara et al., 1993). In another 
study, intracellular GSH levels in rat primary neuronal cells were found to be maintained 
by transport of extracellular L-cysteine (Kranich et al., 1996). The SNB-19 cell line 
appears to mirror these findings by possessing an alternative transporter for the GSH 
precursor L-cysteine. It is interesting to speculate that in addition to supplementing its 
own GSH reservoirs, SNB-19 cells may be able to clear glial-released L-cysteine from 
the synapse and thereby starve neurons from GSH precursors. Neuronal cells appear to 
be more vulnerable to oxidative damage and this transport of L-cysteine into SNB-19 
cells may decrease GSH levels in proximal neurons leaving them susceptible to apoptotic 
or excitotoxic death.
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Table 5.1. Varying levels of Cl -dependent L-glutamate transport rates in human glioma 
cells grown under similar conditions.
Cell Line Vn^(pmok/min mg protein) Km(KM)
SNB-19 1410 ± 72 (n=4) 111 ± 10 (n=4)$
U-373 553±116(n=4)* 177 ± 8 (n=4)
SW-1088 437 ± 79 (n=4)* 109 ± 6  (n=4)$
CCF-STTGl 349 ± 65 (n=4)* 104 ± 14 (n=4)$
Results are reported as mean ± SEM for at least four separate experiments 
conducted in duplicate and are corrected for non-specific uptake (e.g., leakage and 
binding) by substracting the amount of pH]-L-glutamate accumulated at 4 °C. Both 
specific and non-speciEc transport rates were determined in the presence of Cl and 
absence of Na  ̂(equimolar substitution with choline). Lineweaver-Burk plots and 
associated kinetic parameters were estimated by computer analysis using k.cat kinetic 
program (BioMetallics Inc.) with weighting based on constant relative error (refer back to 
Rgure 4.1 p. 49). * Denotes values significantly less than SNB-19 Cl -dependent L- 
glutamate transport rates, p < 0.01; $ Denotes Kg, values signiEcantly less than U-373 
values, p < 0.01.
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Figure 5.1. Varying amounts of total intracellular GSH levels in four human glioma cell 
lines grown under similar conditions.
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Total intracellular glutathione levels (GSH + GSSG) were determined through a 
recycling assay and are reported as nmols/mg protein ± SEM (n) in cells 90 to 95% 
confluent grown in identical media and conditions. Data for each determination was 
based on 13-16 separate experiments in which total GSH levels were measured from 
single wells in duplicate. GSH levels are as follows: SNB-19 = 67 ± 3 (22), CCF- 
STTGl = 55 ±3  (19), SW-1088 = 38 ± 2 (19), and U-373 = 34 ± 2  (20). *Denotes values 
significantly less Aan SNB-19 intracellular GSH levels, p < 0.01; $ Denotes values 
significantly less than CCF-STTGl inhacellular GSH levels, p < 0.01.
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Figure 52. Total intracellular GSH amounts are minimally raised in the presence 
of increasing L-cystine and L-cysteine levels.
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Total intracellular glutathione levels (GSH 4- GSSG) were determined through a 
recycling assay and are reported as nmols/mg protein ± SEM (n) following a 24 hr. 
incubation period. Data for each determination was based on at least three separate 
experiments in which total GSH levels were determined in duplicate. Media changes 
were performed every three to four days. Control L-cysdne and L-cysteine 
concentradons in the growth media on these days were 100 and 125 ;/M  respecdvely. At 
the beginning of the incubadon period when cells were 90 to 95% confluent, L-cysdne or 
L-cysteine was added to designated wells without a media change to give a maximal 
concentradon of that listed for the amino acids in the inset and the cells were harvested 
24 hours later. * Denotes values significantly greater than control GSH values, p < 0.01.
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Figure 5.3. GSH levels are similarly reduced in the tumor cell lines by the y- 
glutamylcysteine synthetase inhibitor BSO.
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Total intracellular glutathione levels (GSH + GSSG) were determined through a 
recycling assay and are reported as % of control ± SEM (n) following a time course study 
on cells 90-95% confluent. Data for each determination was based on at least three 
separate experiments in which total GSH levels were determined in duplicate. Control L- 
cystine and L-cysteine concentrations in the growth media were 100 and 125 pM 
respectively. At the beginning of the 24 hr incubation period, BSO (500 pM ) was added 
to designated wells without a media change and cells were harvested at the following 
time points. * Denotes a value signiAcantly less than GSH amounts found in the SNB-19, 
CCF-STTGl, and U-373 at the 24 hr. time point in the presence of BSO (500 pM ), p < 
0.05.
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Figure 5.4. Total intracellular GSH levels precipitously drop in the presence of the 
system non-transportable inhibitor.
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Total intracellular glutathione levels (GSH + GSSG) were determined through a 
recycling assay and are reported as % of control ± SEM (n) following a 24 hr incubation 
period on cells 90-95% confluent. Data for each determination was based on at least 
three separate experiments in which total GSH levels were determined in duplicate. 
Control L-cystine and L-cysteine concentrations in the growth media were 100 and 125 
pM respectively. At the beginning of the 24 hr incubation period, amino acid transporter 
blockers were added to designated wells without a media change to give a total inhibitor 
concentration of that listed in the inset. * Denotes values significantly less than control 
GSH values, p < 0.01. $ Denotes values significantly greater than total GSH (GSH + 
GSSG) amounts found in the other three cell lines in the presence of 4-S-CPG (250 pM).
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Figure 5 .5. Total intracellular GSH levels are dropped to varying degrees following 
administration of the system x, inhibitor 4-S-CPG.
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Total intracellular glutathione levels (GSH 4- GSSG) were determined through a 
recycling assay and are reported as % of control ± SEM (n) following a time course study 
on cells 90-95% confluent. Data for each determination was based on at least three 
separate experiments in which total GSH levels were determined in duplicate. Control L- 
cystine and L-cysteine concentrations in the growth media were 100 and 125 pM 
respectively. At the beginning of the 24 hr incubation period, 4-S-CPG (250 pM) was 
added to designated wells without a media change and cells were harvested at the 
following time points. * Indicates a value significantly greater than intracellular GSH 
levels found in the other three cell lines at the 24 hour time point, p < 0.01.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
72
Table 5.2. Replenishment of total intracellular GSH levels with increasing L- 
cysteine and L-cystine amounts during transporter-mediated insult with 4-S-CPG.
Total Intracel ular Glutathione ^vels (% of control)
SNB-19 CCF-STTGl SW-1088 U-373
Control 100 ± 4  (22) 100 ±5  (19) 100 ±5  (19) 100 ± 6  (20)
4-S-CPG (250 pM) 40 ± 3 (16) 20 ± 2  (13) 13 ±3  (12) 18 ±3 (14)
4-S-CPG (250 pM)
4-
L-cysteine (500pM)
78 ± 2  (3)** 58 ± 2  (3 )**,$ 47 ± 8  (3 )**,$ 53 ± 18 (3)
4-S-CPG (250 pM)
■4-
L-cystine (500pM)
81 ± 6  (5)** 80 ± 9  (5)** 7 4 ±1 3 (5 )** 62 ± 12 (6)**
Total intracellular glutathione levels (GSH + GSSG) were determined through a 
recycling assay and are reported as % of control ± SEM (n) following a 24 hr incubation
period on cells 90-95% confluent. Data for each determination was based on at least 
three separate experiments in which total GSH levels were determined in duplicate. 
Control L-cystine and L-cysteine concentrations in the growth media were 100 and 125 
pM respectively. At the beginning of the 24 hr incubation period, 4-S-CPG and 4-S-CPG 
with the amino acids L-cysteine or L-cysdne were added to control media in designated 
wells to give a total concentration of that listed in the table. **Denotes values 
significantly greater than 4-S-CPG (250 pM) GSH amounts, p < 0.01. ^Denotes values 
significantly less than SNB-19 GSH levels found in the presence of 4-S-CPG (250 pM ) + 
L-cysteine (500 /<M), p < 0.01.
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Figure 5.6. Total intracellular GSH levels are further reduced following 
administration of the system ASC cellular amino acid transporter blocker with 4-S- 
CPG in the SNB-19 cell line.
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Total intracellular glutathione levels (GSH -i- GSSG) were determined through a 
recycling assay and are reported as % of control ± SEM (n) following a 24 hr incubation 
period on cells 90-95% confluent. Data for each determination was based on at least 
three separate experiments in which total GSH levels were determined in duplicate. 
Control L-cystine and L-cysteine concentrations in the growth media were 100 and 125 
pM respectively. At the beginning of the 24 hr incubation period, 4-S-CPG and 4-S-CPG 
with the amino acid transporter blockers: L-T-2,4 PDC system XAo, L-N^-PCP-G system 
ASC, or BCH system L were added to designated wells without a media change to give a 
total concentration of that listed in the inset. *Denotes values significantly less than 
GSH values found in the presence of solely 4-S-CPG, p < 0.05.
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Chapter 6: Conclusions:
The work presented in this thesis furthers our understanding of system x, and 
leads to many exciting questions. The first portion of this study presents an experimental 
technique that allows the cellular efflux of L-glutamate through system x̂  to be followed 
in real time by coupling its metabolism by glutamate dehydrogenase to the fluorometric 
detection of NADPH. This approach provides an effective strategy to delineate the 
structural requirements necessary for substrate transport (i.e. translocation) in contrast to 
the competition assays, which provide insight only on the process of binding. The 
finding that acyclic glutamate analogues, L-homocysteate and L-seiine-O-sulphate are 
partial substrates at system x̂  also raises some interesting questions. These compounds 
both have sulfur containing moieties replacing the distal carboxylate and this anionic 
group substitution may be a strategy to synthesize more effective substrate/inhibitors. 
Interestingly, the two most potent competitive inhibitors, L-quisqualate and 4-S-CPG, 
were found to be the least active as substrates. These compounds are both cyclic 
glutamate analogues whose function at the transporter contrasts sharply with the system 
Xg substrate ibotenate. These Andings may prove useful in computer-based molecular 
modeling studies aimed at generating substrate and non-substrate inhibitor 
pharmacophores.
The results of this dissertation may also aid in the development of future glioma 
therapeutic strategies. Thus the ability to deliver cytotoxic or imaging agents to tumor 
cells via system x̂  could prove beneficial, as could GSH (GSH4GSSG) depletion and 
subsequent radiosensitization through cystine transport inhibition. System x /
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upregulation in CNS-derived tumor cells relative to expression levels in primary 
astrocytes is a biochemical process that could be manipulated to specifically target 
glioma cells in vivo. Knowledge of an inhibitor pharmacophore of system x̂  could be 
used to synthesize compounds directed at blocking the cystine/glutamate obligatory 
exchanger. This may attenuate the transport of needed amino acids (i.e. L-cystine) and 
make the tumor cells more vulnerable to radiation- or chemotherapy- based treatments. 
Details of a system x̂  substrate pharmacophore could be used to synthesize fluorescent 
or radioactive imaging agents to quantify the amount and location of metastatic tumor 
growth in the CNS. Also, cytotoxic compounds could be generated that serve as system 
Xg substrates which prove lethal to glioma cells once transported inside.
In the second portion of work, P-N-oxalyl-L-a,p-diaminopropionic acid (P-L- 
ODAP), a non-protein glutamate analogue believed to be the causative agent underlying 
the motor nemon degeneration and spastic paraparesis in human neurolathyrism was 
studied. It is believed that thé interaction of P-L-ODAP with EAA receptors is a 
causative factor in the progression of neurolathyrism. However, our studies and others 
have shown that this non-protein amino acid interacts at other sites and the sum of its 
actions may contribute to its pathological properties. In order to define the interactions of 
P-L-ODAP with system x ,, the radiolabel-uptake and fluorometrically- coupled assays 
were used. P-L-ODAP was found to not only be a competitive inhibitor, but to also 
exhibit substrate activity comparable to that of the endogenous substrate L-cystine.
These findings and the observations that P-L-ODAP has the ability to specifically destroy 
neurons in certain regions of the spinal cord (e.g. ventral horn cells around the thoracic 
pyramidal tract) raises some interesting questions. The abili^ of system x̂  to transport
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and accumulate P-L ODAP could limit its access to EAA receptors. It may be of interest 
to define regions of system expression through immunocytochemisty studies. With 
the generation of antibodies specific for the xCT subunit this analysis may be possible. 
Once accumulated in certain cells, p-L-ODAP would also have access to intracellular 
targets. It may be of interest to specifically define targets (e.g. enzymes or receptors) 
inside cells that makes neurons and glia vulnerable to P-L-ODAP- mediated 
pathogenesis.
Lastly, we investigated the relationship between levels of system x̂  activity and 
the maintenance of intracellular glutathione concentrations in several glioma- derived cell 
lines. Using the chloride-dependent L-fH]-glutamate radiolabel- uptake assay, we 
demonstrate high levels of system activity in the four CNS- derived tumor cell lines. 
Using the GSH recycling assay, we were able to determine total intracellular GSH levels 
and elucidate possible physiolological roles that system x̂  may play in maintaining this 
intracellular thiol. By comparing the effect of system x̂  inhibitors, such as 4-S- 
carboxyphenylglycine, with other inhibitors of glutathione biosynthesis, such as 
buthionine sulfoximine, on glutathione levels, the contribution of the transporter in 
supplying extracellular precursors for this antioxidant could be estimated. We observed 
that inhibition of system x̂  led to a time- dependent decrease in intracellular glutathione 
levels. However, we also found that the levels of system x̂  activity varied among the 
cell lines, even though the rates of glutathione utilization appeared similar. These results 
suggest that the amount of cystine transported through this system may not always be a 
rate limiting factor in glutathione homeostasis. It may be of interest to extend these 
findings to cell survivability studies to determine if GSH depletion has varying levels of
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impact on cell survival in the four glioma lines. This may include observing whether 
cells are made more sensitive to radiation or chemotherapeutic insult following system 
inhibition and subsequent GSH depletion.
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